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G-protein coupled receptors (GPCRs) are one of the largest families of membrane proteins which 
play a fundamental role in the signaling cascades that maintain physiological homeostasis. In this 
research, we focused on an important member of the endocannabinoid system, the CB1 receptor, 
which is primarily expressed in the neurons of the central and peripheral nervous system. 
Chapter 2 focuses on structure-activity relationships to identify chemical functionalities on the 
indole-2-carboxamides (the scaffold for ORG27569) that maintain allostery at the CB1 receptor. 
These novel analogs were evaluated for their binding affinity at the allosteric site (KB) and the 
impact of these analogs on orthosteric ligand binding (α). Paradoxically, these analogs activated 
CB1 yet decreased G-protein coupling. Evaluation of the impact of these analogs on different 
pathways demonstrated that these analogs activate β-arrestin 1 mediated pathways. Chapter 3 
focuses on optimizing another scaffold for allostery at the CB1 receptor, pyrimidinyl 
biphenylureas. The scaffold was generated by replacing the pyridine ring of PSNCBAM-1 with 
pyrimidine and analogs of this scaffold were evaluated for allosteric parameters. Similar to 
indole-2-carboxamides, these positive allosteric modulators of CP55,940 binding, reduced G-
protein  coupling. These compounds hold promise to develop anti-obesity drugs. Chapter 4 
focuses on identification of motifs on the CB1 receptor which are key for binding allosteric  
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modulators ORG27569 and PSNCBAM-1. I leveraged the finding that these modulators bind 
CB1 but not CB2, and identified one extracellular region of CB1 that impact ORG27569 binding. 
No impact on PSNCBAM-1 was seen, suggesting that this ligand may bind to a different site on 
the CB1 receptor. These results will aid in the identification of amino acid residues that may play 
a key role in allosteric ligand binding. 
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Chapter 1 
Introduction 
1.1 The G protein-coupled receptor superfamily 
G-protein coupled receptors (GPCRs) represent one of the largest families of proteins in the 
mammalian genome (Lander et al., 2001; Venter et al., 2001). Around 750 genes out of 35,000 
human genes encode for GPCRs. Their tertiary structure is characterized by seven 
transmembrane α-helices connected by intracellular and extracellular loops. On the intracellular 
surface, these receptors are associated with a heterotrimeric G-protein. These receptors respond 
to various stimuli including ions, amines, proteins, peptides, lipids and even photons and 
transduce signals across the biological membrane (Fredriksson et al., 2003). GPCRs are involved 
in many fundamental physiological functions. The importance of GPCRs is evident as more than 
half of currently known therapeutic drugs target these receptors (Flower et al., 1999; Komatsu et 
al., 2015), yet only a minority of these receptors has been exploited therapeutically (Vassilatis et 
al.,2003). Therefore these receptors offer potential targets for drug discovery.  
1.2 GPCR classification system 
One of the first classifications of GPCRs was based on sequence homology and classified 
GPCRs into six classes as shown in Figure 1.1. These classes and their prototype members are as 
follows: Class A (rhodopsin-like), Class B (secretin receptor), Class C (metabotropic glutamate), 
Class D (fungal mating pheromone receptors), Class E (cyclic AMP receptors) and class F 
(frizzled/smoothened) receptors. This classification includes all the known GPCRs including 
those from vertebrates and invertebrates. The classes were further divided into subclans and were 
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assigned roman numbers. The family D and E which represents fungal pheromone receptors and 
cAMP receptors do not exist in humans. Also, in class A, the subclan IV includes invertebrate 
opsin receptors and (Attwood and Findlay 1994; Kolakowski, 1994) and class F which contains 
archebacterial opsins is not part of GPCRs found in humans. 
Due to the large sequence differences between mammalian and invertebrate GPCRs, this 
classification was severely hampered. Fredrikkson et al., in 2003, introduced a different system 
which used large scale phylogenetic analyses of human GPCRs to establish five main families of 
GPCRs. The system is called the GRAFS system and includes glutamate (G, 22 members), 
rhodopsin (R, 672 members), adhesion (A, 33 members), frizzled/taste 2 (F, 36 members) and 
secretin (S, 15 members) families. The rhodopsin family with the highest number of members is 
further subdivided into 13 groups. Very few human receptors could not be classified into any of 
the groups according to the classification criteria and are called as “other 7TM receptors” 
(Fredrikkson et al., 2003). A key difference in this classification from the previous classifications 
of GPCRs is it separates the secretin and adhesion families which are not seen in Class A-F 
classification. Although the two families have high sequence identity in their transmembrane 
helices (TM), their N-terminus shows high sequence divergence (Scioth et al., 2005).  
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Figure 1.1 Classification of GPCRs. GPCRs have been traditionally classified into 6 classes 
based on sequence homology: class A (rhodopsin), class B (secretin), class C (metabotropic 
glutamate), class D (fungal mating pheromone (VR)), class E (cyclic AMP (cAR)) and class F 
(frizzled/smoothened). Examples of receptors belonging to these classes are written in black. The 
figure is modified from Bockaert et al., 1999. 
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1.3 GPCR ligands and activation states: from a two-state model to multiple-state model 
              In the past, many theories on GPCR activation have been proposed. Most of them are 
based on the theory proposed by Clark which states that a drug, upon binding to a receptor, can 
induce an intracellular signal depending upon what state it fixes the receptor in and it is this 
conformation that defines the transduced action (Clark et al., 1937). 
1.3.1 Two-state equilibrium model 
Traditionally, the process of ligand binding and signaling of GPCRs has been defined by 
a two-state equilibrium model which is based on the principle of change in equilibrium between 
two distinct conformations of the receptor (Leff et al., 1995; Freire et al., 1998; Park et al., 
2008). The ternary complex model is the most commonly used two-state model to describe G-
protein activity. The ternary complex involves three moieties: the receptor (R), agonist (A) and 
the G-protein (G). The activation of the receptor relies on its ability to couple to G-protein and 
thus, it is the receptor-G protein complex which defines the active state of the receptor as shown 
in Figure 1.2. Coupling of the receptor to G protein (RG) results in the active state of receptor 
which displays higher affinity for agonists. On the other hand, the uncoupled state is inactive and 
displays lower affinity for agonists (De lean et al., 1980). 
The notion that conformations between the two states, i.e. the active state (R*) and the 
inactive state (R), exist came after the identification of constitutive active mutants (CAMs) for 
many GPCRs. The first CAM was identified for the β2-adrenergic receptor where mutations in 
the third intracellular loop (IC3) resulted in a mutant with higher affinity for agonists and an 
increase in agonist potency in the absence of G-protein. This could not be accommodated by the 
classical ternary complex model. Therefore, an extended ternary complex model was defined, 
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where the receptor exists in two interconvertible states R and R*, which is an intrinsic property 
of the receptor itself. This model could accommodate the idea of constitutive activity of 
receptors where the mutations that increase the level of constitutive activity shifted the 
equilibrium favoring the R* state as shown in Figure 1.2 (Samama et al., 1993).  
Based on this extended model, agonists were defined as ligands which shifted a larger 
proportion of receptor molecules towards the R* state. The definition of full and partial agonists 
depends on the proportion of receptor molecules shifted to the active state. Inverse agonists 
promote shifting the equilibrium towards the inactive R state. Antagonists are defined as ligands 
which have equal affinity for both R and R* state and have no effect on the basal activity of 
receptors (Park et al., 2008). 
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Figure 1.2 Different models of GPCR activation. (A) the classical model of GPCR activation 
where agonist (A) binds to the inactive receptor (Ri) and forms a complex (ARi), which then 
isomerizes to an active form of receptor (RA) due to the efficacy of agonist. (B) the ternary 
complex model of GPCRs where agonist binding to the inactive receptor causes conformational 
changes in the receptor and activates the receptor. The activated receptor then binds to G protein 
(G) to form a signaling complex (ARAG). (C) The extended ternary complex model which 
incorporates the constitutive signaling from GPCRs. The inactive receptor Ri can isomerize to RA 
independent from the presence of an agonist and interact with G protein.  β and γ are factors by 
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which the affinity of the receptor for G-protein coupling is modified upon activation of the 
receptor either spontaneously or in the presence of an agonist, respectively. (D) the cubic ternary 
complex model, where the inactive receptor can also bind to G protein to form the RiG complex 
which is non-signaling by nature. The factors δ, β and γ define the modification in the affinity of 
receptor for G-protein. Modified from Kenakin et al., 2002.  
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1.3.2 Alternative model describing multiple states of the receptor 
Recent evidence of agonist-directed trafficking of receptor stimulus has led to the notion 
that receptors can exist in multiple conformations between the R and R* state. Different agonists 
induce a spectrum of different conformations of the receptor and it is these conformations that 
define the signaling downstream. They promote binding of different G-proteins or β-arrestins 
which in turn impact downstream signaling. This suggests that theoretically, a receptor can exist 
in a limitless number of conformations, Rn*.  
An example for the existence of multiple signaling states is seen in the dopamine receptor 
D2L. When co-expressed with different G-protein subunits in SF9 cells and analyzing the effect 
of different agonists on membrane preparations, it was seen that different agonists could 
differentially activate different G-protein subunits (Gazi et al., 2003, Perez et. al, 2005). This 
suggests that different agonists may adopt different conformations which can have a varying 
degree of selectivity for the different G-proteins.  
Another example of multiple signaling states can be seen with differences in efficacy of 
ligands for different signaling pathways. In the 5-HT2A receptor, for example, structurally diverse 
ligands from three families, the tryptamine, ergoline and phenethylamine family displayed 
differential efficacy for PLC or PLA2-mediated pathways. This further supports the hypothesis 
that different agonists can display different conformations of GPCRs, thus differing in their 
selective activation of different pathways (Kurrasch-Orbaugh et al., 2003, Perez et al., 2005).  
An alternate model for GPCR activation called cubic ternary complex model exists which 
includes the ideas of extended ternary complex but differs from it in that G-proteins can also 
bind to the inactive receptor in this model as shown in Figure 1.2. This introduced the existence 
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of a complex formed between an inactive receptor and G-protein which does not evoke a 
response and ligand binding to this complex would act as an antagonist or inverse agonist for the 
receptor (Weiss et al., 1996). An example that supports this notion is tiotidine, an inverse agonist 
for the H2 histamine receptor which binds to the receptor coupled to Gs that does not evoke a 
response (Perez et al., 2005). 
1.4 Structural features of GPCRs  
The typical architecture of class A GPCRs includes seven transmembrane helices (TM) with 
three intracellular (IC) and three extracellular loops (EC), a cytoplasmic C-terminus with an α-
helix (H8) parallel to the cell membrane and an extracellular N-terminus (Moreira et al., 2014). 
Many structure-function studies have identified key structural elements in this class of GPCRs 
and have validated the function of these elements. Some of these conserved motifs as shown in 
Figure 1.3 and are discussed below. The residues are numbered according to a numbering system 
by Ballesteros where the first number represents the helix the residue belongs to. The last two 
numbers following the period are denoted to an amino acid based on the number of residues it is 
away from the most conserved residue of the helix which is numbered .50. The residues down 
the helix are numbered as .51, .52 and so on and the residues up the helix are numbered as .49, 
.48 and so on.  
(1) The ionic lock: this represents the strong intermolecular interactions between the 
residues Glu3.49/Arg3.50 of the conserved (D/E)RY motif in the TM3 region with residues 
Glu6.30/Thr6.34 in TM6. These molecular interactions constraint the movements of TM 
helices to maintain the receptor in the inactive state (Ballesteros et al., 1998; Moreira et 
al., 2014). 
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(2) The hydrophobic arginine cage: the conserved Arg3.50 is restrained in its conformation 
by conserved hydrophobic amino acids at positions 3.46 and 6.37.  When GPCRs are 
activated, the Arg3.50 within the (D/E)RY motif adopts an extended conformation and 
points towards the center of the protein core, which results in disruption of its ionic 
interactions with Glu3.49 and Glu6.30. The conserved hydrophobic amino acids form a 
hydrophobic cage surrounding this Arg3.50 so that the GPCR is maintained in its inactive 
state (Ballesteros et al. 1998, Caltabiano et al., 2013). 
(3) The NPxxYxF motif in the TM7 region: This motif is present in the cytoplasmic end of 
TM7. The two most essential residues in this motif are the proline and the tyrosine. The 
proline in this motif forms a kink or distortion in the TM7 α-helical structure. As a result, 
the tyrosine in this motif faces into the pocket formed by TM2, TM3, TM6 and TM7, 
which allows for direct interaction of tyrosine with Phe7.60 in H8 and with the side chain 
and backbone of Arg2.40 in TM2 via water molecules. This aqueous pocket is presumed to 
stabilize the GPCRs in its inactive state. The solvent interactions are weak which allows 
for the ease of breaking of these interactions when an agonist binds and easy switch of 
GPCR to an active state (Edwards et al., 2004; Fujiyoshi et al., 2002; Rosenbaum et al., 
2009). 
(4) The rotamer toggle switch:  Another molecular switch that operates during agonist 
activation of the receptor is the rotamer toggle switch. This refers to the coordinated 
change in the rotameric angles upon binding of a ligand among aromatic residues in 
TM6. The Trp6.48 of the CWxP motif is surrounded by this cluster of aromatic amino 
acids which undergo a conformational change and point towards TM5 in the active state 
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as opposed to the inactive state where these residues point towards the TM7 (Visiers et 
al., 2002; Moreira et al., 2014). 
These structural/functional motifs were earlier published based on computational modeling 
and were later validated by crystal structures (Palczewski et al., 2000; Schousboe et al., 
2003). 
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Figure 1.3 Common structural motifs in GPCRs. (A) 2-D diagram of human rhodopsin (gene 
OPN2) showing three important motifs, (D/E)RY, CWxP and NPxxY motif. Modified from 
Munk et al., 2016. The (D/E) RY motif carries the molecular switch called the ionic lock which 
maintains the receptor in the inactive switch. The CWxP motif carries the molecular switch 
called the rotamer toggle switch, which plays a key role in activation of receptors. (B) Crystal 
structure of rhodopsin (PDB ID: 2X72) highlighting the three motifs. The helix which contains 
the motif is highlighted in green color. Modified from Trzaskowski et al., 2012. 
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1.5 Lifecycle of a GPCR 
In the past few decades, a wealth of information has been gained that reveals the complex life 
cycle a G-protein undergoes. The mechanism by which a GPCR is delivered to the cell surface to 
allow GPCR-ligand interactions and then salvaged from the cell membrane is of paramount 
importance. The main steps involved in the GPCR life cycle are shown in Figure 1.4.  
1.5.1 Biosynthesis 
Before a GPCR reaches the cell surface, a receptor undergoes a continuous process of 
maturation. Nascent GPCRs interact with accessory chaperone proteins in the endoplasmic 
reticulum (ER) (Ellgard et al., 2003). These chaperones ensure the proper folding of the GPCRs 
along with other cell machinery proteins which include: 
(1) Protein disulphide isomerase: which allows disulphide bond formation between unpaired 
cysteines 
(2) Heat shock protein Hsp-70: which masks the hydrophobic surfaces on the protein 
(3) Calnexin and Calreticulin: which interact with immature N-glycosyl chains (Enna et al., 
2011) 
The properly folded proteins are then transported to the endoplasmic-golgi intermediate 
complex (ERGIC) and golgi by packing them into COPII-coated vesicles. The proteins, in the 
golgi, undergo additional modifications including maturation of the glycosylated chains. Strict-
quality control checks in the Golgi apparatus ensure that the misfolded or immature proteins are 
degraded via the proteasome pathway. The properly folded and mature proteins are then 
delivered to the cell surface. (Ellgard et al., 2003; Lefkovitz et al., 2006). 
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Oligomerization and heterodimerization are also believed to play a key role in the 
biosynthesis and trafficking of GPCRs from the ER. Proper targeting of the receptors to the cell 
surface may require heterodimerization of some GPCRs such as α1D-AR which needs to dimerize 
with a closely related α1B-AR for its transport and expression on the cell surface (Hague et al., 
2004, Lefkovitz et al., 2006).  Multiple GPCRs like vasopressin (Terrillon et al., 2003; Lefkovitz 
et al., 2006) and β2-adrenergic receptors (Salahpour et al., 2004), undergo homodimerization in 
the early stages of synthesis, mostly in the ER. Thus, dimerization of receptors also plays a key 
role in synthesis and trafficking of receptor, atleast for some of the GPCRs. 
1.5.2 Maintaining cell surface stability of receptors 
Not only is the proper folding and transport of a receptor to the cell surface important, it 
is very vital to ensure the stability of the receptor once it resides in the cell membrane to ensure 
proper ligand interactions. Many proteins have been identified, which play a key role in 
stabilizing the receptors at the plasma membrane. These include muskelin, protein 4.1N, Homer, 
actin binding protein 280/filamin A, postsynaptic density-95 (PSD-95) and sphinophilin (Tan et 
al., 2004). PSD-95, for example interacts with the C-terminus of the β1-adrenergic receptor and 
maintain its stability at the cell surface, as is evident from decreased receptor internalization on 
overexpression of PSD-95 (Xiang et al., 2002). 
1.5.3 GPCR signaling and the role of guanine exchange factors (GEFs) 
A vast array of ligands such as photons, small molecules, hormones, proteins can activate 
GPCRs. For the GPCR to signal, a heterotrimeric G-protein has to dissociate into its α and βγ 
subunits. GDP-bound α subunit tightly binds to the βγ subunit. When a GPCR is bound to an 
agonist, the agonist GPCR complex acts as a GEF and causes exchange of GDP for GTP at the 
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G-protein, which promotes dissociation of G-protein into its subunits, which then couple to 
various effector molecules to stimulate downstream signaling pathways. 
Other than the GPCR itself, there are many other reported GEFs that have been reported to 
trigger G-protein signaling pathways independent of the receptor. Dexras 1, for example, has 
been reported as a putative GEF for activation of Gαi subunits (McCudden et al., 2005). 
Another group of proteins reported to play an important role in G-protein signaling independent 
of GPCRs are AGS (activators of G-proteins). These accessory proteins act as GEFs at the G-
proteins and play a key role in regulation of GPCR signaling (Cismowski et al., 2005). 
1.5.3 Endocytosis of GPCRs 
Extensive information has been gathered in the past regarding the endocytotic trafficking 
of GPCRs. Proteins identified to play a key role in endocytosis are the G-protein receptor kinases 
(GRKs) and β-arrestins (non-visual arrestin). Additional accessory proteins work with the GRKs 
and arrestins for endocytosis to take place. Upon activation of a receptor by agonists, a GPCR 
becomes prone to phosphorylation by GRKs. β-arrestins bind to the phosphorylated receptors 
which terminate the G-protein signaling and the arrestin bound receptors move to endosomes for 
degradation or lysis (Hanyaloglu et al., 2008). Agonist-independent phosphorylation of receptors 
is also demonstrated by GPCRs, although the rate of internalization is slower. β2-adrenergic 
receptors, for example, in the presence of agonist, are sequestered from the cell surface with a 
half-life of 10 mins but in the absence of an agonist, the receptors stay on the cell-surface for 
more than an hour (Zastrow et al., 1994).  
Two isoforms of β-arrestins have been demonstrated to be important for desensitization 
and sequestration of heptahelical proteins. These are arrestin 2 (β-arrestin 1) and arrestin 3 (β-
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arrestin 2). Although both β-arrestin 1 and β-arrestin 2 are involved in the endocytotic cycle, the 
two isoforms differ in their abilities to desensitize and sequester the receptors. In β2-adrenergic 
receptor, for example, it was demonstrated using knockout mice for β-arrestin 1 or β-arrestin 2 
that it is the β-arrestin 2 form that is 100-fold more potent than β-arrestin 1 for sequestration of 
receptors. However, both β1 KO mice and β2 KO mice displayed similar levels of impairment of 
agonist-stimulated desensitization. The role of the two isoforms of arrestin can be different for 
different GPCRs. For example, in angiotension I type 1A receptor (AT1A-R), the two isoforms 
displayed equal levels of impairment of agonist-stimulated desensitization. However, for 
internalization, the β1 KO mice showed slight impairment whereas the β2 KO mice showed no 
change (Kohout et al., 2001). 
The β-arrestin bound receptors may be endocytosed by formation of three types of vesicles: 
clathrin-coated, caveolin-coated or uncoated vesicles (Claing et al., 2002). Clathrin-coated 
endocytosis is implicated in endocytosis of many GPCRs. The process begins at the plasma 
membrane by the formation of a coated pit in the membrane. The arrestin-bound receptors form 
interactions with adaptor proteins (particularly AP2) and cluster in the growing coated pit. 
Adaptor protein-2 (AP2) interacts with binding sites for phosphatidylinositol-2-phosphate (PIP2) 
to interact with plasma membrane. PIP2 is a lipid that is highly concentrated in the plasma 
membrane (Robinson et al., 2004). AP2 recognizes short sequence motifs in the cytoplasmic 
domains of internalized proteins such as YXX-phi, where X can be a variable and phi represents 
a bulky hydrophobic amino acid (Ohno et al., 1995; Sorkin et al., 2004). The adaptor proteins 
link the membrane proteins and clathrin, which causes co-assembly of cargo proteins, adaptors 
and clathrin. The protein amphiphysin, then dimerizes at the neck of the coated-vesicle formed 
and the GTPase enzyme binds to amphiphysin and drives cleavage of the neck of the vesicle and 
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the coated pit is released and moves to the endosomes (Robinson et al., 1994; Schmid et al., 
1997). 
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 Figure 1.4 Different stages in the GPCR life cycle. (A) After synthesis of GPCRs, the receptors 
undergo processing and folding in the ER. Chaperone and quality-control proteins ensure proper 
folding and sending the unfolded proteins to a proteasome pathway. GPCRs also undergo homo- 
or hetero-dimerization while in the ER. The properly folded proteins are sent through the Golgi 
apparatus where GPCRs may undergo additional modifications and then are transported to the 
cell surface. Many proteins, as shown, ensure cell stability of GPCRs. B, GPCRs, upon persistent 
agonist activation are phosphorylated by GRKs and β-arrestin binds to the phosphorylated 
receptor. The internalization machinery proteins such as AP-2 and clathrin are recruited by β-
arrestin and the receptors are transported to the clathrin-coated pits for endocytosis. The protein 
dynamin plays a key role to knick the clathrin pit, which causes endocytosis of the receptor. 
After endocytosis, the receptors are either de-phosphorylated and recycled to the cell surface or 
degraded by lysosomes. Two classes of GPCRs exist based on their interaction with β-arrestins. 
Class A GPCRs represent those GPCRs where the interaction with β-arrestins is transient and the 
GPCRs goes alone in the endocytotic vesicles without the arrestins. This includes receptors such 
as dopamine D1A, β2AR, µ opioid receptor and endothelin 1A. Class B includes those GPCRs 
where the receptor bound to β-arrestin goes into the endocytotic vesicle thus representing a non-
transient interaction (Shenoy et al., 2003). Modified from Lefkowitz et al., 2006. 
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1.6 Allosteric modulation of GPCRs 
Recent research in GPCRs has shifted focus to identifying ligands which bind to a 
topographically distinct site than the one where the endogenous ligands bind (orthosteric site). 
These sites are called allosteric sites and the ligands which bind at these sites to modulate 
receptor activity are called allosteric modulators as shown in Figure 1.5. GPCRs are naturally 
allosteric because G-proteins allosterically modulate agonist binding.  
1.6.1 Types of allosteric modulators 
There are four types of allosteric modulators: 
(1) Potentiators or positive allosteric modulators (PAMs): ligands that increase receptor 
function. The positive modulation can be seen by an increase in agonist affinity or 
efficacy. PAMs can also function by blocking desensitization of the receptor (Burford et 
al., 2012).   
(2) Allosteric antagonists or negative allosteric modulators (NAMs): ligands that decrease 
receptor function through decrease in agonist affinity or efficacy. 
(3) Allosteric agonists (Ago-allosterics or ago-agonists): allosteric compounds which display 
positive modulation in the absence of the orthosteric ligand.  
(4) Silent allosteric modulators (SAMs): ligands that bind at the allosteric site but do not 
modulate the receptor function. 
20	
	
 
Figure 1.5 Different types of allosteric interactions. Orthosteric ligands (shown in green) 
bind at the site, where the endogenous ligands bind and cause conformational changes which 
causes downstream signaling. PAMs (shown in yellow) bind at the allosteric site and may 
increase the binding affinity of orthosteric ligand or efficacy of the orthosteric ligand. NAMs 
decrease the binding affinity or efficacy of the orthosteric ligand. SAMs are ligands which 
bind at the allosteric site but have no impact on the binding affinity and efficacy of 
orthosteric ligand. The G-protein with its three subunits is shown in orange. Modified from 
Wootten et al., 2013. 
1.6.2 Therapeutic benefits of allosteric modulators 
Allosteric ligands have a number of advantages over their orthosteric counterparts as therapeutic 
agents. First, allosteric modulators show higher subtype specificity than orthosteric ligands. 
Since allosteric sites have not undergone a high evolutionary pressure, allosteric sites do not 
have a high sequence identity between subtypes and thus targeting these sites could help develop 
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subtype-specific drugs (Conn et al., 2009). Such subtype specificity with allosteric modulators 
has been reported for many GPCRs such as adenosine receptors (Goblyos et al., 2011) and 
metabotropic glutamate receptors (Lindsley et al., 2004). Second, allosteric sites offer an 
opportunity to develop therapeutics for receptors where targeting the orthosteric site has not 
yielded successful drugs. For example, for the GLP-1 receptor no orthosteric agonists have been 
identified yet but allosteric agonists have been reported (Knudsen et al., 2007; Burford et al., 
2011). Third, unlike orthosteric drugs, allosteric modulators may have an effect only when the 
endogenous ligand is present and thus maintain the temporal and spatial characteristics of 
endogenous signaling. PAMs, for example, may amplify the endogenous signaling but the 
temporal regulation of signaling is not affected. This could be of great importance especially 
with neurotransmitters where the timing of signaling is very important. The spatial 
characteristics of endogenous signaling are also maintained because unlike orthosteric ligands 
which can potentially act on every tissue that expresses the receptor, allosteric modulators can 
impact signaling only where the endogenous ligand acts (Conn et al., 2009; Burford et al., 2011). 
Fourth, orthosteric ligands cause significant downregulation of receptors due to constant firing of 
the receptors. Since allosteric activity may not be constant as it may depend on the endogenous 
signaling, in some instances these modulators offer potential for lesser desensitization of 
receptors (May et al., 2007). Fifth, allosteric activity has a ceiling effect and thus can be used to 
develop ligands with better safety profiles than orthosteric ligands where there is an increase in 
modulation of the receptor with increasing concentrations and no ceiling effect (Wild et al., 
2013). 
The practical advantages of the allosteric modulators led to two marketed drugs that 
target the allosteric sites on GPCRs i.e. Cinacalcet and Maraviroc. Cinacalcet is a positive 
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allosteric modulator of the calcium sensing receptor (CaSR). It is approved for treatment of 
primary and secondary parathyroidism (Messa et al., 2008). Cinacalcet interacts with the 
allosteric pocket between the 6th and 7th TM (Miedlich et al., 2004).  Maraviroc, on the other 
hand, is a negative allosteric modulator of CCR5 chemokine receptor, approved as an anti-HIV 
drug. It allosterically inhibits the binding of two CCR5 ligands, RANTES and MIP1a (Hughes et 
al., 2009). Both the drugs exhibit enhanced safety profiles which exemplify the advantages of 
developing allosteric modulators from a drug discovery point-of view (Burford et al., 2011). 
1.6.3 Detection and quantification of allostery 
Many different radioligand binding or functional assays can be used to detect and quantify 
allostery at GPCRs. The simplest method to validate allostery at GPCRs is to perform 
equilibrium binding assays. Such binding assays can define two important parameters for 
allostery: KB, which is the equilibrium dissociation constant of the allosteric modulator which 
defines the affinity of the allosteric modulator for the receptor; and α, the cooperativity factor 
which defines the magnitude and direction of impact the allosteric modulator and orthosteric 
ligand have on each other when both occupy the receptor. When α>1, the ligand is a positive 
allosteric modulator whereas when α<1, the ligand is a negative allosteric modulator. α=1 
denotes no allosteric modulation. The two parameters are calculated based on allosteric ternary 
complex model (Christopoulos et al., 2002; Price et al., 2005) which is as follows: 
Y= [A]/{[A]+(KA (1+[B]/KB)/(1+α [B]/KB))} 
where Y represents the fractional specific binding; KA and KB are the equilibrium dissociation 
constants for the orthosteric and allosteric ligands respectively; [A] and [B] are the 
concentrations of the orthosteric and allosteric ligand, α is the cooperativity factor. Another 
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method to detect the above two parameters through radioligand binding assays is to perform 
kinetic assays to determine the impact of allosteric compounds on the association or dissociation 
of orthosteric ligands. PAMs increase the association kinetics or decrease the dissociation 
kinetics of the orthosteric agonists. NAMs, on the other hand, increase the dissociation kinetics 
or increase the association kinetics of the orthosteric agonists.  Apart from radioligand binding 
assays, functional assays such cAMP assays, calcium assays can also be performed to identify 
allosteric interactions of ligands with the orthosteric ligand. Functional assays allow readouts 
which can easily be translated into therapeutic functions that the allosteric modulator may have 
by investigating the signaling pathway of interest (May et al., 2007)  
Two important characteristics of allosteric modulators need to be considered while 
analyzing allosteric modulator curves. First, allosteric modulators may display probe dependence 
which means that the allosteric activity of a modulator may be biased for a given orthosteric 
probe. This means that a modulator can vary in nature and magnitude of allosteric activity 
depending on the orthosteric ligand (Kenakin et al., 2005). For example, LY2033298 is a 
positive modulator of binding affinity of Ach at the M4 mAch receptor, but shows no modulation 
for two pharmacophorically different antagonists, N-methylscopolamine and quinuclidinyl 
benzilate (Leach et al., 2010; Keov et al., 2011). 
Another important characteristic of allosteric modulation, which adds to the complexity of 
these ligands, is the possibility of functional selectivity or stimulus bias. In simplified terms, it 
means that a ligand can be a positive allosteric modulator for some pathways associated with a 
receptor and have a negative modulation or no impact on others. Such selectivity for modulation 
of certain pathways has been exhibited by some allosteric modulators (Urban et al., 2007). For 
example, the allosteric modulator of M1 mAch receptor, VU0029767 positively modulates 
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intracellular calcium mobilization of acetylcholine but is neutral for phospholipase D-mediated 
pathways (Marlo et al., 2009). Another example of such selectivity is demonstrated by 1-(4-
ethoxyphenyl)-5-methoxy-2-methylindole-3-carboxylic acid, which is an allosteric modulator for 
CRTH2 receptor. This modulator acts as an allosteric antagonist for β-arrestin mediated 
signaling of prostaglandin D2 but is neutral for prostaglandin D2-mediated signaling via G-
protein pathways (Mathiesen et al., 2005). This functional selectivity for different pathways 
suggest that multiple functional endpoints need to be evaluated to screen allosteric modulators 
for GPCRs and clinical efficacy of such modulators may be determined by a mix of efficacy of 
these compounds for different pathways. Such functional selectivity also offers opportunities to 
develop pathway selective therapeutics from these allosteric modulators. 
1.7 Crystal structures of GPCRs: what have we learned 
GPCRs are the target for more than 40% of marketed drugs (Hopkins et al., 2006, Komatsu 
et al., 2015). Drug targeting of these receptors has focused on synthesizing ligands which are 
structurally related to the endogenous ligand and thus, can bind and activate the endogenous 
pathways or can bind and block the signaling of the receptors. However, drug discovery with 
GPCRs has been severely impeded by the lack of crystal structures of GPCRs, which hinder our 
understanding of the mechanisms of binding of these drugs.  
Membrane proteins are particularly difficult to crystallize due to the highly hydrophobic 
surfaces of these proteins and the instability of flexibility of these proteins which make them 
difficult to solubilize, purify and crystallize (Carpenter et al., 2008). Due to the advancement in 
structural biology techniques, the last decade has seen a boom in the number of crystal structures 
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obtained for GPCRs which provide us with a wealth of information about the inactive and active 
states of GPCRs and the different interacting motifs of GPCRs. 
In 1993, the first 2-D crystal structure of rhodopsin was obtained (Schertler et al., 1993) 
which was followed by a high resolution crystal structure in 2000 (Palczewski et al., 2000). 
Since then, many crystal structures of rhodopsin in inactive (Li et al., 2004; Okada et al., 2004; 
Standfuss et al., 2007) and active states (Salom et al., 2006; Park et al., 2008; Scheerer et al., 
2008; Standfuss et al., 2011; Choe et al., 2011) have been determined. Rhodopsin is a visual 
pigment found in the photoreceptor cells of retina, which transduces signals from photons to 
allow perception of light (Hubbard et al., 1958). The structure of bovine rhodopsin bound to 11-
cis-retinal as shown in Figure 6 revealed key features common to the GPCR family. The primary 
architecture showed seven transmembrane helices connected by three intracellular and 
extracellular loops, an extracellular N-terminus and an intracellular C-terminus. The EC2 loop 
was the longest of the extracellular loops and involved in ligand binding.  
The ligand-binding pocket is highly hydrophobic and is located on the extracellular surface 
of the transmembrane helices. The key residues that stabilize the binding of retinal include the 
residues Met207, Phe208 and Phe212 from H5, and Trp265 and Trp268 from TM6 (Palczewski 
et al., 2000; Li et al., 2004; Okada et al., 2004; Standfuss et al., 2007). The receptor is 
maintained in its inactive state by an interaction between the Arg135 from TM3 and Glu246 
from TM6, which is commonly referred to as the “ionic lock”. In the inactive receptor, the TM6 
shows a bend at 36° formed by Pro267 which keeps both the ends of the transmembrane away 
from the core of the transmembrane bundle. The C-terminus of the receptor shows a short 
amphipathic helix called H8, which is perpendicular to TM7 and anchors the receptor covalently 
to the membrane via palmitoylation of Cys322 and Cys323. The C-terminus includes important 
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sites of phosphorylation which includes Ser334, Ser338 and Ser343, which are recognized upon 
phosphorylation by arrestins to arrest G-protein signaling. The intracellular loop 3 (IC3) is highly 
flexible and disordered in the inactive state of rhodopsin (Zhou et al., 2012). 
Upon activation, several conformational changes are seen in the motifs that were stabilizing 
the inactive state of the receptor as shown in Figure 1.6. Upon exposure to light, the cis-retinal 
undergoes a cis-trans transition that is responsible for activation of the receptor. Changes in the 
conformation of the receptor occur to allow binding of G-protein on the intracellular side. The 
TM6 at Pro267 bends further away from the TM core on the intracellular side and a crevice of 
14Å diameter for G-protein binding is formed (Scheerer et al., 2008; Standfuss et al., 2011; Choe 
et al., 2011). As a result of bending of TM6, the ionic lock which constraints the receptor in an 
inactive state breaks. The NPXXY motif on TM7 shifts towards TM6 and orients Tyr306 
towards the helix, which also aids in breaking the ionic lock. The C-terminus of TM5 is 
elongated due to addition of majority of IC3 loop into TM5 to provide interface to the G-protein 
for coupling to the receptor (Zhou et al., 2012). 
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Figure 1.6 Comparison of inactive and active state crystal structures of rhodopsin (A) Inactive 
state crystal structure of rhodopsin (in cyan, PDB:1F88) with 11-cis retinal (in pink) showing 
some of the key residues that stabilize the ligand in the binding pocket (B) Superimposed 
inactive (in cyan, PDB:1F88) and active state (in green, PDB: 3PQR) crystal structure of 
rhodopsin revealing conformational changes in retinal upon photoactivation with all-trans retinal 
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shown in red and the ground state 11-cis retinal in pink. (C) Superimposed structures of inactive 
(in cyan) and active (in green) conformations of rhodopsin. The H6 shows an outward movement 
on the cytoplasmic end (as shown by a horizontal arrow) by bending at Pro 267 which creates a 
crevice for G-protein to bind. The H5 elongates on the cytoplasmic end and creates a larger 
interface for G-protein interaction. Adopted and modified from Zhou et al., 2012. 
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The structure of rhodopsin established the basis of our understanding of GPCRs, however this 
receptor is unusually very stable with cis-retinal keeping it in a non-signaling conformation. 
However, most of the GPCRs are highly flexible and equilibrate between multiple 
conformational states upon ligand binding (Kobilka et al., 2007). The crystal structure of the β2-
adrenergic receptor helped to gain insight into the key interactions that stabilize such GPCRs due 
to the high basal activity exhibited by this receptor. The inactive state crystal structure shown in 
Figure 1.7 was obtained with antagonist carazolol bound to the receptor and a T4L fusion protein 
was inserted at EC3 to stabilize the protein. The crystal structure revealed that the extracellular 
loops of the receptor allow entry of the ligand into the binding pocket which is formed by TM3, 
TM5, TM6, TM7 and the EC2 loop. The ionic lock which maintains GPCRs in an inactive state 
was in open conformation which suggests the high basal activity of this receptor 
(Moukhametzianov et al., 2011). Some of the key interactions which stabilized the binding of 
carazolol in the binding pocket included a salt bridge between the ammonium moiety and 
Asp3.32, hydrogen bonding of the hydroxyl group with Asn7.39 and between aromatic groups of 
carazolol and Ser5.42 (Rosenbaum et al., 2007; Warne et al., 2008; Shonberg et al., 2015). In 
2011, an agonist-bound β2-AR crystal structure was solved in complex with a covalent ligand 
FAUC50. They key interactions that stabilized the agonist-bound structure were hydrogen bonds 
between catechol-replacing ring of FAUC50 and Ser5.42 and Ser5.46 (Rosenbaum et al., 2011).  
Crystal structures of the receptor with partial agonists lacked hydrogen bonding with Ser5.46 
suggesting weaker binding interactions in the orthosteric pocket. These crystal structures 
revealed structural differences between agonists and partial agonists that correlate with their 
efficacy at the receptor (Warne et al., 2011). 
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Overall, around 20 different receptors from the class1A rhodopsin-like family have been solved 
in complex with different ligands. These crystal structures have been the basis of structure-based 
drug design, homology modeling of receptors with unknown structures and virtual ligand 
docking. It has allowed a better appreciation of the structural understanding of GPCRs and laid 
the basis for a more refined and targeted drug design (Shonberg et al., 2015).  
 
Figure 1.7 Crystal structures for β2-adrenergic receptor. The crystal structure shows the inverse 
agonist carazolol (shown in red) bound to the receptor. Some of the key interactions that stabilize 
the ligand are formed with Asp3.32, Ser5.42 and Asn7.39 as shown in the figure. Modified from 
Shonberg et al., 2015. 
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1.8 The endocannabinoid system 
The endocannabinoid system primarily consists of two receptor subtypes i.e. CB1 and 
CB2 (Pertwee et al., 1997), the ligands acting at these receptors naturally synthesized in the body 
called endocannabinoids and the enzymes involved in their biosynthesis, transport and 
metabolism (Petrocellis et al., 2004). Screening of orphan GPCRs for binding to THC resulted in 
the identification of the CB1 receptor (Devane et al., 1988; Bram et al., 2012). Later, the CB2 
receptor was identified by homology cloning (Munro et al., 1993). The two major 
endocannabinoids include anandamide (N-arachidonyl-ethanolamine) (AEA) (Devane et al., 
1992) and 2-arachidonylglycerol (2-AG) (Sugiura et al., 1995). Other proposed 
endocannabinoids include N-arachidonoyl-dopamine (NADA), noladin ether and virodhamine 
(Petrocellis et al., 2004). Recently, a nonapeptide known as hemopressin has been identified as 
the first endogenously synthesized CB1 inverse agonist, although further investigation of its 
pharmacology is needed (Heimann et al., 2007). 
Biosynthesis of AEA occurs in a two-step process as shown in Figure 1.8. First, transfer 
of arachidonic acid from the sn-1 position of phosphatidyl choline to the nitrogen atom of 
phosphoethanolamine (PE) is mediated by a calcium-dependent transacylase to form N-
arachidonoyl PE (NAPE). This acts as the precursor for AEA synthesis. A NAPE-specific 
phospholipase D (NAPE-PLD) enzyme then hydrolyzes NAPE to yield AEA (Marzo et al., 
2009). However, no reduction in AEA levels were exhibited in NAPE-PLD knockout mice 
which led to the identification of alternate enzymes and pathways involved in AEA synthesis 
(Leung et al., 2005). These include alpha-beta hydrolase 4 which sequentially cleaves sn-1 and 
2-acyl groups of NAPE to generate glycerophospho-AEA which is hydrolyzed by 
phosphodiesterase to yield AEA. Another biosynthetic route involves the enzyme phospholipase 
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A2 which converts NAPE into 2-lyso-NAPE which is then followed by action of 
lysophospholipase D (Liu et al., 2008).  
For the hydrolysis of AEA, the main enzyme involved is fatty acid amide hydrolase 
(FAAH) which hydrolyzes AEA to its corresponding fatty acids (shown in Figure 1.8). FAAH 
has emerged as an attractive target in recent studies since FAAH inhibitors can increase the 
endogenous levels of AEA which can maintain the temporal and spatial control of the CB1 
receptor as against a CB1 agonist which can potentially activate all the receptors in the body and 
not maintain the timing of signaling. This can be used for the treatment of pain, inflammation 
and sleep disorders (Otrubova at el., 2011).   
The biosynthesis of 2-AG has also been largely investigated and the chief enzymes for 2-
AG biosynthesis are diacylglycerol lipase (DAGL) α and β (Bisogno et al., 2003). Phospholipase 
C hydrolyzes phosphatidylinositol or phosphatidic acid to generate DAG precursors which are 
hydrolyzed to 2-AG by DAGL. Monoacylglycerol lipase is the main enzyme involved in 
degradation of 2-AG (Blankman et al., 2007). Other alternate enzymes involved in 2-AG 
degradation are ABHD-6 (α,β-Hydrolase domain containing 6) and ABHD-12.  
Recent evidence has suggested some non-CB1 and non-CB2 receptors bind the 
endocannabinoids. This includes the orphan receptor GPR55, a receptor with <20% sequence 
homology with CB1 and CB2. This receptor is activated by CP55,940 and demonstrates GTPγS 
binding with anandamide and virodhamine (Ryberg et al., 2007). Further investigations are 
needed to understand the pharmacology of this receptor. 
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Figure 1.8 The endocannabinoid system represented in pre- and post-synaptic neurons. The two 
important endocannabinoids, AEA and 2-AG are shown with the enzymes involved in their 
synthesis and degradation. The enzymes involved in biosynthesis of anandamide are NAT (N-
acyltransferase), NAPE (N-arachidonyl phosphatidylethanolamine), NAPE-PLD (N-arachidonyl 
phosphatidylethanolamine phospholipase D), NAPE-PLC (N-arachidonyl 
phosphatidylethanolamine phospholipase C) and phosphatase. Anandamide is inactivated by 
FAAH (fatty acid amide hydrolases). 2-AG is biosynthesized by PLC (phospholipase C) and 
DAGL (diacylglycerol lipase) and inactivation by MAGL (mono-acyl glycerol lipase) 
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1.9 Localization and tissue distribution of cannabinoid receptors 
The CB1 receptor is primarily expressed in the central nervous system (CNS) and is present on 
the presynaptic terminals (Katona et al., 1999; Marsicano et al., 1999, Tsou et al., 1999). 
However, recent studies have revealed that the CB1 receptor is also expressed in peripheral 
tissues such as reproductive (Pertwee et al., 2001), digestive (Croci et al., 1998) and 
cardiovascular systems (Szabo et al., 2001). In the CNS, the CB1 receptor is predominantly 
expressed in the hippocampus, caudate, putamen, globus pallidus, accumbens nucleus and 
horizontal limb of the diagonal band as shown in Figure 1.9 (Svizenska et al., 2008). These are 
important regions of the brain that influence mood, motor coordination, sensation, memory, 
cognition and autonomic function. The expression patterns of the receptor in the CNS can be 
correlated with many effects associated with cannabinoids. For example, the hippocampus region 
is involved in learning and memory processes and a high density of CB1 receptors in this region 
relates to why chronic exposure to marijuana and other cannabinoids can impair memory and 
cognition (Herkenham et al., 1990; Herkenham et al., 1991b). Alterations in the expression of the 
CB1 receptor in different parts of the brain have been attributed to the progression of diseases 
such as Parkinson’s (Glass et al., 1993) and Huntington’s disease (Sanudo-Pena et al., 1998). 
Differences in CB1 expression levels between rat and human cerebellum explains why defects in 
gross motor functioning following marijuana use are subtle in humans compared to rats where 
acute administration of cannabinoids results in deleterious effects on motor function in the form 
of immobility, ataxia and catalepsy (Ameri et al., 1999; Herkenham et al., 1990). CB1 receptors 
have been suggested as a therapeutic target for pain management, which is explained by the high 
expression of the CB1 receptor in the periaqueductal gray and dorsal horn of the spinal cord. CB1 
35	
	
is expressed in the majority of the nociceptive neurons in the dorsal root ganglia with variable 
degrees of CB1 mRNA detected in the dorsal root ganglia.  
The CB1 receptor also plays a key role in regulation of food intake, metabolism of lipids 
and glucose and fat accumulation both centrally and peripherally. Rimonabant (also called 
SR141716A), an inverse agonist of CB1, was commercially available in the European market as 
an anti-obesity drug. Upon stimulation of CB1 in the hypothalamus, CB1 may interact and 
regulate the neuropeptides involved in food intake and lipogenesis such as corticotropin-
releasing hormone (MCH), prepro-orexin, cocaine-amphetamine-regulated transcript (CART). 
The dopaminergic reward pathway is invigorated upon CB1 stimulation in the accumbens 
nucleus which leads to motivation to eat and intake drugs of abuse (Maldonado et al., 2006).  
Regions with moderate density of CB1 expression include neocortex, medial 
hypothalamus, solitary nucleus and basal amygdala. Very low levels of CB1 are seen in the 
thalamus and brain stem (Svizenska et al., 2008).  
CB2 receptors are considered to be peripheral cannabinoid receptors due to their primary 
expression in the immune system. In immune cells, CD4+ T cells, CD8+ Tcells, B cells, batual 
killer cells, monocytes and polymorphonuclear neutrophils show highest CB2 density (Derocq et 
al., 1995; Schatz et al., 1997; Dittel et al., 2008; Atwood et al.; 2010). Apart from the immune 
system, expression of CB2 receptors is also reported in bone cells such as osteocytes, osteoblasts 
and osteoclasts where they modulate bone growth (Ofek et al., 2006). Other regions of CB2 
expression include adipocytes (Roche et al., 2006), hepatic myofibroblasts (Julien et al., 2005), 
the trabecular meshwork cells in the eye (He et al., 2007), cardiomyocytes (Shmist et al., 2006) 
and sperm cells (Grimaldi et al., 2009).  
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Although considered to be a peripheral cannabinoid receptor, recent murine and rat 
studies have detected expression of CB2 in the brain although the density of expression is much 
lower than CB1. Microglia, the resident immune cells of the brain which monitor pathological 
damage in the brain show CB2 mRNA and protein (Meresz et al., 2007; Beltramo et al., 2006). 
Migration of microglia to neurodegenerated areas in the brain is modulated by CB2 (Atwood et 
al., 2010). RT-PCR studies to quantify mRNA, protein and functional expression have shown the 
expression of CB2 mRNA in the brainstem in rats. The presence of CB2 mRNA has also been 
reported in the granule cells and Purkinje cell layers in the mouse cerebellum (Atwood et al, 
2010). 
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Figure 1.9 Tissue distributions of cannabinoid receptors in the body. The different systems of 
the body where CB1 (in blue), CB2 (in yellow) or both CB1 and CB2 (in green) are shown. The 
CB1 receptor is primarily expressed in the CNS. Some of the key regions where CB1 is expressed 
include hippocampus, basal ganglia, cortex and cerebellum. Lower expression levels are seen in 
amygdala, nucleus accumbens, thalamus, hypothalamus and spinal cord. CB2 is primarily 
expressed in the immune system cells such as macrophages, B and T-lymphocytes, neutrophils 
and monocytes. CB2 expression is also seen in bone cells, spleen and skin nerve fibres. Although 
low, expression of CB1 is also been demonstrated in some areas of the CNS such as astrocytes, 
microglial cells and brainstem neurons. 
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1.10 Cannabinoid ligands and inactive-active state models 
Research involving cannabinoid ligands developed from investigations on the plant 
material from marijuana (Cannabis Sativa). Since then, a number of CB1 ligands, both natural 
and synthetic have been identified. CB1 agonists can be divided into four major groups: classical 
cannabinoids, non-classical cannabinoids, aminoalkylindoles and eicosanoids. Recently, another 
class of agonists for CB1 have been synthesized which are called hybrid cannabinoids. 
Classical cannabinoids: The classical cannabinoids include the main psychoactive component 
of marijuana, ∆9-THC; the equally active isomer of THC, ∆8-THC and other active constituents 
from the plant material such as cannabidiol (CBD), cannabinol (CBN) and cannabichromene 
(CBC) (Pertwee et al., 2008). The classical cannabinoids also include synthetic analogs 
synthesized using ∆9-THC which includes potent analogs such as 1ʹ ,2ʹ -dimethylheptyl-pyran 
(DMHP) and  (-)-11-∆8-THC-dimethylheptyl (HU-210). These ligands have a tricyclic ring 
system with a benzopyran moiety. The members of this group usually lack selectivity between 
CB1 and CB2 for binding. For example, ∆9-THC is a partial agonist for both CB1 (Ki= 39.5 nM) 
and CB2 (Ki= 40 nM). HU-210 is a potent cannabinoid ligand but lacks subtype-specificity (Ki 
for CB1=0.7 nM and Ki for CB2= 0.2 nM) (Pertwee et al., 2005).  
Non-classical cannabinoids: The non-classical cannabinoids include bicyclic (e.g. CP55,940) 
and tricyclic (e.g. CP55,244) analogs of ∆9-THC developed by Pfizer. These ligands lacked the 
dibenzopyran ring present in classical cannabinoids since structure-activity relationship (SAR) 
studies on classical cannabinoids revealed that the benzopyran ring is not essential for activity 
and elimination of the pyran oxygen to make open phenol analogs showed higher affinity. 
CP55,940 shows higher affinity (Ki= 0.6 nM) and efficacy compared to ∆9-THC (Ki= 39.5 nM). 
However, like ∆9-THC, CP55,940 non-selectively binds to both CB1 and CB2. In the structure of 
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non-classical cannabinoids, it is the side chain and phenol that are key for maintaining activity at 
the cannabinoid receptors. The stereochemistry of the hydroxpropyl chain prefers a β-
conformation although the chain is not necessary for activity (Reggio et al., 2008). 
Hybrid Cannabinoids: This class of ligands was reported by the Makriyannis group and 
combined all the structural features of classical and non-classical cannabinoid ligands. These 
ligands used a southern aliphatic hydroxyl pharmacophore (SAH) not present in plant 
cannabinoids. The structure allowed three-dimensional access to the active sites which was not 
possible with the non-classical ligands. Using the SAH pharmacophore and optimizing it by 
introducing double bonds or triple bonds at the C2ʹ ʹ  position in the hydroxypropyl chain led to 
hybrid probes such as AM938 (Thakur et al., 2005). 
Aminoalkylindoles: The prototypical ligand for this group is WIN-55,212-2, the structure of 
which bears no resemblance to classical or non-classical cannabinoids. First synthesized by the 
Sterling Research Group, WIN-55,212-2 has a high affinity for both CB1 (Ki= 1.89 nM) and CB2 
(Ki= 0.28 nM). SAR on this structure by revealed that the aminoalkyl moiety in the molecule can 
be substituted for straight chain alkyl groups (Huffman et al., 1994). This lead to indole 
derivatives such as JWH-007 (1-pentyl-2-methyl-3-(1-naphthoyl)indole) with a high affinity for 
CB1 (Ki=9.5 nM) and CB2 (Ki= 2.9 nM) and JWH-015, the 1-propyl analog with a high affinity 
for CB2 (Ki= 13.8 nM) (Reggio et al, 2008).  
Eicosanoids: This class includes fatty acid derivatives that are endogenously synthesized 
cannabinoid ligands i.e. endocannabinoids. These are synthesized locally on demand and utilize 
cell membrane components for their biosynthesis. AEA and 2-AG are the primary 
endocannabinoids. AEA is easily hydrolyzed by FAAH (Deutsch et al., 1993). 2-AG is 
considered a primary endocannabinoid because it is present in higher amounts in the brain 
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although it has a lower binding affinity for CB1(Ki=472 nM) compared to anandamide (Ki= 61 
nM). Other ligands belonging to this category are 2-arachidonyl glyceryl ether (Noladin ether), 
virodhamine, N-docosatetraenoylethanolamine and N-arachidonoylglycine. Noladin ether shows 
a high binding affinity towards CB1 (Ki= 21 nM) than CB2 (Ki= >3000 nM) (Svizenska et al., 
2008).  
Inverse agonists 
Hyperactivity of the endocannabinoid system is associated with the progression of many 
diseases. CB1 hyperactivity has been associated with diseases such as obesity, overweight and 
the associated cardiovascular risks and substance abuse disorders for which inverse agonists of 
CB1 have gained mounting interest. The first CB1 inverse agonist, SR141716A, was first 
developed at Sanofi-Aventis and displayed a high affinity for CB1 (Ki= 1.8 nM) and a reduced 
affinity for CB2 (Ki= 514 nM). SR141716A affects the constitutive signaling of CB1 promoting 
signaling responses opposite to those of agonists. It abrogates the constitutive G-protein 
signaling of CB1. It antagonizes the inhibitory effects of CB1 agonists on cAMP levels in rat 
brain membranes (Rinaldi-Carmona et al., 1994). Clinical effectiveness of rimonabant in obesity 
was based on its metabolic effects such as enhanced lipid oxidation and decreased lipogenesis in 
liver. However, reduction in food consumption with the drug is transient, which questions its 
ability to be an effective weight-control medicine (Henness et al., 2006; Patel et al., 2007). In 
2008, this drug was withdrawn due to psychoactive side effects such as anxiety and depression 
associated with the drug (Kirilly et al., 2012). Other than SR141716A, AM251 and AM281 are 
inverse agonists of CB1 with a diarylpyrazole pharmacophore. Capable of competing with 
SR141716A in CB1 receptor membrane preparations, these ligands exhibit antagonizing 
properties to CB1 agonists similar to SR141716A (Thakur et al., 2005). 
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Antagonists 
Due to the side effects seen with inverse agonists of the CB1 receptor, another 
pharmacological strategy to manipulate the CB1 receptor that has emerged is the development of 
antagonists. Unlike CB1 inverse agonists, these ligands do not affect the constitutive activity of 
CB1 and thus only affect ligand-dependent CB1 activation. Theoretically, the side effects seen 
with inverse agonists may be due to the abrogation of basal signaling tone of CB1 receptor. 
Several antagonists of the CB1 receptor have been developed. VCHSR, an analogue of 
SR141716A attenuates WIN55,212-2 induced inhibition of Ca2+ signaling by CB1. However, as 
a neutral antagonist, it does not exhibit this effect in the absence of WIN55,212-2 unlike 
SR141716A. VCHSR lacks the hydrogen bonding in its C3 substituted region as exhibited by 
SR141716A (Hurst et al., 2002). 
 Another series of CB1 antagonists were developed as sulphonamide analogs of Δ8-THC with 
acetylenic side chains to yield O-2050 which showed neutral antagonism in mouse isolated vas 
deferens (Martin et al., 2002; Pertwee et al., 2005). Another analogue of SR141716A, NESS 
0327 has been reported. NESS 0327 shows high specificity for CB1 (Ki= 0.00035 nM) as 
opposed to CB2 (21 nM) with 60000 times more readily binding to CB1 than CB2 and is more 
potent as an antagonist than CB1 (Ruiu et al., 2003; Pertwee et al., 2005). 
Structures of some of the important ligands discussed above along with their binding affinities at 
CB1 receptor are shown in Figure 1.10.  
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Figure 1.10 CB1 ligand structures and Ki values for binding at CB1 receptor. Representative 
agonists (classical, non-classical, aminoalkylindoles and endocannabinoids), antagonists and 
inverse agonists of CB1 are shown with Ki values in brackets (Ki values reported from Pertwee et 
al., 2010). 
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1.11 Signaling via CB1 receptors: G-protein dependent and independent-pathways 
 
The CB1 receptor is involved in multiple downstream signaling pathways which can be 
dependent on G-protein or could involve G-protein independent pathways. On activation by 
ligand, CB1 receptors undergo conformational changes and on the intracellular side of the 
receptor, a heterotrimeric G-protein binds. There is a guanosine-nucleotide exchange of GDP for 
GTP and the G-protein dissociates into α and βγ subunits which are coupled to downstream 
effector molecules which drive different signaling pathways as shown in Figure 1.11. 
CB1 primarily couples to Gi/o protein which on activation causes inhibition of adenylate cyclase. 
Coupling to Gi/o protein may also lead to manipulation of different ion channels (Howlett et al., 
1986). CB1 activation causes stimulation of G-protein coupled inwardly rectifying potassium 
channels through Gi/o protein (Mackie et al., 1995). In cerebral vessels, it has been reported that 
CB1 activation causes inhibition of L-type calcium channels (Gebremedhin et al., 1999). 
Inhibition of N-type calcium channels has also been previously reported, which may be 
important for retrograde signaling by CB1 (Brown et al., 2004).  
Under certain circumstances such as treatment with pertussis toxin (PTX), CB1 may couple to Gs 
protein, which causes activation of cAMP formation via activation of adenylate cyclase (Glass & 
Felder 1997, Abadji et al. 1999, Calandra et al. 1999, Kearn et al. 2005). Certain cannabinoid 
ligands have been reported to generate signaling via activation of Gq/11 protein. For example, 
HEK293 cells expressing the CB1 receptor, when treated with the CB1 agonist WIN55,212-2 
causes a Gq-mediated calcium signaling (Lauckner et al., 2005). However, in NG108-15 cells, 
calcium signaling induced upon CB1 stimulation was pertussis-toxin sensitive suggesting the 
involvement of Gi/o protein (Sugiura et al., 1996), indicating that these cell-type specific results 
could be a result of different G-protein pools in different cell types. The CB1 receptor also 
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activates pathways associated with mitogen-activated protein kinases (MAPKs). Activation of 
MAPKs can lead to pathways that ultimately activate phosphorylation of ERK1/2 (Howlett et al., 
2005), c-Jun N-terminal kinase (JNK), p38 MAPK or ERK5 proteins (Turu et al., 2010). 
Activation of the CB1 receptor leads to phosphorylation of ERK1/2 in a variety of cell types. 
Mechanisms leading to ERK1/2 activation include activation of Gi/o proteins (Howlett et al., 
2005), phosphatidylinositol 3-kinase (Galve-Roperh et al., 2002), Src tyrosine kinase 
(Derkindersen et al., 2003) and G-protein independent mechanisms mediated by β-arrestins 
(Turu et al., 2010).  
Stimulation of the CB1 receptor has been reported to activate JNK1/2 and p38 in a variety 
of cells. In Chinese hamster ovary (CHO) cells, stimulation of CB1 via THC leads to activation 
of JNK-1/2 and p38 MAPK. Activation of JNK was mediated by Gi/o proteins (Reuda et al., 
2000). In rat hippocampal cells, p38 MAPK was activated by cannabinoids but no JNK1/2 
activation was seen (Derkindersen et al., 2011). In Neuro 2a cells, ERK1/2 stimulation but not 
JNK1/2 or p38 activation was seen following treatment with HU-210 (Graham et al., 2006; Turu 
et al., 2010).  
Other partners that CB1 interacts with include adaptor protein AP-3 (Rosenfeld et al., 2008), 
adaptor protein FAN (Sanchez et al., 2001) and GPCR-associated sorting protein (GASP-1) 
(Martini et al., 2007) to control signaling and trafficking. Overall, the CB1 receptor demonstrates 
the principle of stimulus trafficking where different ligands can evoke different signaling 
pathways depending upon the G-protein coupling and effector molecules stimulated. 
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Figure 1.11 Complex signaling pathways followed by cannabinoid receptor activation. Both CB1 
and CB2 primarily couple to Gi/o and cause inhibition of adenylyl cyclase activity decreasing 
cAMP levels. CB1 regulates many ion channels such as Ca2+ and K+ channels. It causes negative 
regulation of voltage-gated Ca2+ channels and positive stimulation of inwardly-rectifying (Kir) 
and voltage-dependent (KA) potassium channels. CB1 receptor is also involved in activation of 
MAPK family causing phosphorylation of ERK1/2, JNK and p38. Coupling of CB1 to Gs protein 
has been reported in some cell lines and cause activation of adenylyl cyclase. CB1, under certain 
conditions may couple to Gq protein which causes release of intracellular Ca2+. Adopted and 
modified from Bosier et al., 2010. 
 
46	
	
1.12 Functional motifs on the CB1 receptor: orthosteric binding site  
It is now well understood that different ligands may induce different conformational states which 
in turn governs the G-protein it couples to. Different functional residues may be involved in 
binding of different class of ligands in the orthosteric binding pocket. The complexity in 
understanding binding efficacy of ligands in GPCRs is further heightened because most of the 
known X-ray crystal structures available for GPCRs are for the inactive state of the receptor 
(Edwards et al., 2004; Cherezov et al., 2007; Warne et al., 2008; Zazula et al.,2008) because the 
receptor is very dynamic in the active state and difficult to crystallize. No X-ray crystals are 
available for the CB1 receptor. However, multiple functional residues have been identified for 
CB1 through a combined approach of mutational analyses and computational modeling. 
Homology models are often built for CB1 for docking ligands using X-ray crystal structures from 
the rhodopsin family. Sequence alignment with rhodopsin and others such as β2-adrenergic 
receptor, alpha-adrenergic receptor 2A (AA2A R) show that CB1 shares some motifs that are 
conserved in GPCRs, which have been previously discussed in this chapter. Functional residues 
important for ligand binding that have been identified through mutagenesis require careful 
examination because introduction of a point mutation in a receptor can greatly alter the ligand-
binding properties.  
The key initial contacts of CP55,940 binding to the CB1 receptor involved TM3-E2-TM5 
region. At a later stage of receptor activation, TM6 and TM7 are also involved. The residues 
identified through many different mutagenesis studies have identified F268, P269, H270 and 
I271 in the extracellular loop 2 (EC2) (Ahn et al., 2009) and Y2755.29 (McAllister et al., 2002) 
and C3556.47 (Picone et al., 2005) as the residues which form direct contact with CP55,940 for 
binding to the CB1 receptor. Computational modeling studies have suggested that S3837.39 is 
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important to maintain a kink in the TM7, which is necessary for CP55,940 binding. Loss of 
CP55,940 binding occurs when this residue is mutated to alanine which causes reduction in the 
TM7 kink (Kapur et al., 2007). Thus, this residue results in an indirect loss of binding through 
the conformation formed that results in a loss of activation. For the aminoalkylindoles 
particularly WIN55,212-2, the aromatic microdomain in the TM3-4-5 and TM6 is the proposed 
region of binding. The residues which form a direct contact for WIN55,212-2 binding include 
G1953.31 (Chin et al., 1999), F2003.36 (McAllister et al., 2003), Y2755.39 (McAllister et al., 2007), 
W2795.43 (McAllister et al., 2003) and V2825.46 (Song et al., 1999). Another residue important 
for WIN55,212-2 binding is D1632.50, a highly conserved residue in GPCRs. The mutant D163N 
exhibits a 400-fold loss of binding of WIN55,212-2 and loss of cAMP signaling. Although the 
residue does not form direct contacts with WIN55,212-2, this mutation results in an altered 
ligand binding pocket and thus play a critical role in the binding of WIN55,212-2 to the CB1 
receptor (Abood et al., 1998). 
AEA, an endocannabinoid for the CB1 receptor, primarily binds in the TM2-3-5 region. 
Not many contacting residues for anandamide binding are known. Y2755.39 is involved in H-
bonding with AEA, since 13-fold loss of binding in a Y275F mutant and a complete loss of 
ligand binding in a Y275I mutant was observed. Another important residue involved in direct 
contacts with anandamide is F1893.25 which forms aromatic/π interactions with the C5-C6 double 
bond of anandamide. 
SR141716A, the highly subtype-specific inverse agonist for CB1 binds in the TM3-5-6-7 
region. The binding site is located deep in the receptor core and residues in direct contact with 
SR141716A include F2003.36, W2795.43, W3566.48 (McAllister et al., 2003) and C3867.42 (Fay et 
al., 2005). The two residues, W2795.43 and W3566.48 are part of the aromatic microdomain of 
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CB1. The residues which indirectly affect SR141716A include C257 and C264 from the EC2 
loop (Fay et al., 2005), which when mutated to alanine results in loss of SR141716A binding. 
The authors suggested that mutation of these cysteines to alanine may result in loss of intra-loop 
disulfide bonds, causing a conformation change that affects the ligand binding pocket 
architecture.  
A residue K1923.28 has been reported to be a crucial amino acid which is involved in 
binding of CP55,940, anandamide, SR141716A and HU-210. Mutations to this residue have 
been reported to modify the geometry of the binding pocket such that the mutated receptors show 
complete loss of binding for CP55,940, HU-210 and anandamide and 17-fold loss of 
SR141716A in K192A receptors (Song et al., 1996; Chin et al., 1998; Hurst et al., 2002). 
Overall, the key residues for diverse classes of ligands discussed above suggest that 
although there is an overlap in the motifs for binding ligands to CB1, each class of ligands shows 
some unique interactions with CB1 which may dictate the functional selectivity seen with these 
ligands.  
 
1.13 Mechanism of Activation of CB1 Receptor: inactive to active state transition  
         Modeling and mutagenesis studies have helped to determine the multi-step activation of  
the CB1 receptor with agonists such as CP55,940 as shown in Figure 1.12. The ligand CP55,940 
interacts with the residues	 F268E2, P269E2, H270E2, I271E2, Y2755.29 and C3556.47. Aromatic 
interactions are formed between F268 and Y275 with the aromatic ring of the ligand. The C3 
side chain of CP55,940 embeds deep in the core.  
             The residue W3566.48, which is a part of the rotamer toggle switch, has been shown by 
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homology models to be molecularly constrained by aromatic stacking interactions with F2003.36 
and F1702.57 and an extensive H-bond network formed by residues C3556.47, L3596.51, C3837.38 
and  C3867.42.  This extensive network of H-bonds is broken by the interaction of the 
hydrophobic C3 chain of CP55,940 with L3596.51. This causes interference with the CWxP motif 
and the W3566.48 is freed from the molecular constraints to rotate. Coupling movements of TM5 
and TM7 by ligand binding allows rotation of TM6. Due to this, the C3556.47 residue whose side 
chains are embedded in the core in inactive CB1 is now exposed and accessible to CP55,940. The 
activation switch for breaking ionic locks in GPCRs involves N3897.45 and D1632.50. The 
hydrogen bond between N389 and D163 breaks when the TM6 moves outwards. This causes 
N389 to come in contact with TM6. Also upon receptor activation, Y2945.58 and Y3977.52 come 
closer and contribute to breaking the ionic lock (Shim et al., 2009; Shim et al., 2010).  
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Figure 1.12 Schematic representation of the series of steps of activation of CB1 receptor upon 
binding of CP55,940. Based on an inactive model of CB1 (Shim et al., 2010), activation of CB1 
receptor to generate G-protein signaling involves a sequence of changes at molecular level to 
transfer signal from extracellular to intracellular side. These include binding of ligand (as shown 
in yellow) which causes coupling of EC2 loop to TM5/TM7 (as shown in purple). The residue 
W3566.48 of the proposed rotamer toggle switch moves to break the H-bond between W3566.48 
and N3897.45 (as shown in pink). Interactions between L2073.43 and N3937.49 (as shown in 
orange) and interaction between Y2945.58 and Y3977.52 (as shown in cyan) occurs which act as 
the internal switches to allow breakage of the ionic lock between R2143.50 and D3386.30 (as 
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shown in green). As a result, rigid body movements occur in TM6 and TM7 which expands a 
crevice on the intracellular side and allows receptor activation. Modified from Shim et al., 2010. 
To generate the inactive state model, the software MODELLER was used.  
 
1.14 Allosteric modulation of CB1 receptor 
Identification of several allosteric modulators of CB1 have opened opportunities to develop 
subtype-specific modulators since most of the orthosteric ligands for CB1 known so far bind non-
specifically to both CB1 and CB2. Some of the known allosteric modulators for the CB1 receptor 
include 5-chloro-3-ethyl-N-(4-(piperidin-1-yl)phenethyl)-1H-indole-2-carboxamide 
(ORG27569) (Price et al., 2005), 1-(4-chlorophenyl)-3-(3-(6-(pyrrolidin-1-yl)pyridin-2-
yl)phenyl)urea (PSNCBAM-1) (Horsewill et al., 2010) , 3-(4-chlorophenyl)-5-(8-methyl-3-p-
tolyl-8-azabicyclo[3.2.1]octan-2-yl)isoxazole (RTI-371) (Navarro et al., 2009) and the 
endogenous ligand (5S,6R,9E,11Z,13E,15S)-5,6,15-trihydroxyicosa-9,11,13-trienoic acid 
(lipoxin A4) (Pamplona et al.,2012), which are positive allosteric modulators of CB1. Negative 
allosteric modulation of the CB1 receptor has been reported by a new family of peptide 
endocannabinoids (Pepcans) (Bauer et al., 2012). 
ORG27569 is a prototypical allosteric modulator for CB1 receptor. First developed and 
synthesized at Organon, UK, the pharmacological profile of this compound is interesting. It 
increases the binding affinity of CP55,940, an orthosteric agonist of CB1. However, it decreases 
CP55,940-induced G-protein coupling at CB1 receptor (Price et al., 2005; Ahn et al. 2012). A 
similar trend is seen with PSNCBAM-1. Thus, although these compounds are positive allosteric 
modulators of CP55,940 binding, they are antagonists for G-protein coupling. Previously, the 
Kendall lab showed that ORG27569 binding to the CB1 receptor induces ERK1/2 
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phosphorylation in a Gi protein-independent manner. Yet, they showed that it acts as a positive 
allosteric modulator for signaling mediated by β-arrestin-1. It was further demonstrated that 
ORG27569 activates the receptor and enhances its affinity for CP55,940 (Ahn et al., 2012). 
Not only do the allosteric modulators of CB1 show pathway specificity, they also exhibit probe 
dependence. A group of researchers evaluated the impact of ORG27569 and PSNCBAM-1 on 
different pathways with three classes of orthosteric agonists i.e. CP55,940 (classical 
cannabinoids), WIN55,212-2 (aminoalkylindoles) and anandamide (endocannabinoids) (Baillie 
et al., 2013). In GTPγS assays in mouse brain membranes, both ORG27569 and PSNCBAM-1 
displayed a concentration-dependent decrease in Emax of induced G-protein coupling by 
CP55,940, WIN55,212-2 and anandamide. However, a lesser reduction in GTPγS levels was 
seen with WIN55,212-2-induced G-protein coupling than those with CP55,940 and anandamide. 
The effect of ORG27569 on CB1 agonist-mediated inhibition of forskolin-stimulated cAMP 
production was measured in cell membranes epressing hCB1R. ORG27569 reduced the 
inhibition of CP55,940-mediated inhibition of foreskolin-stimulated cAMP production with the 
signaling completely abolished at 10 nM ORG27569. However, it was less effective in reducing 
WIN55,212-2-mediated inhibition of foreskolin-stimulated cAMP production. In contrast to the 
inhibitory effects, ORG27569 increases the ERK1/2 phosphorylation levels induced by 
CP55,940. No significant effect was seen on WIN55,212-2 mediated ERK1/2 phosphorylation 
levels. This clearly demonstrates the probe dependence exhibited by ORG27569. (Baillie et al., 
2013). 
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1.15 Therapeutic potential of CB1 receptor  
        Three cannabinoid ligands are commercially available which are Sativex, Cisamet and 
Marinol. All three are cannabis-based therapeutics with ∆9-THC as the active ingredient. Marinol 
and Cesamet are approved for nausea and vomiting in cancer and AIDS patients and Sativex is 
approved for treatment of neuropathic pain and plasticity in patients with Multiple Sclerosis. 
However, other than the conditions stated above, cannabinoid receptors have been implicated to 
have therapeutic potential for treatment of many disorders.  
The cannabinoid-based therapeutics that have received most attention are the antagonists and 
inverse agonists of CB1, primarily as anti-obesity drugs. CB1 receptors, when activated promote 
expression of fatty-acid synthase in hepatocytes  and hypothalamus (Osei-Hyiaman et al., 2005) 
and activity of lipoprotein lipase in adipocytes (Cota et al., 2003). Thus, CB1 receptors regulate 
energy balance both centrally and peripherally. CB1 antagonists and inverse agonists, in 
preclinical studies have demonstrated a decrease in food consumption and long-term efficacy in 
weight loss (Black et al., 2004). Apart from weight loss, CB1 antagonists and inverse agonists 
demonstrate improved lipid metabolism through peripheral mechanisms. Thus, these compounds 
show promise for developing anti-obesity drugs. Rimonabant (Acomplia) or SR141716A, an 
inverse agonist for CB1 was commercially available as anti-obesity drug but was withdrawn from 
the market due to psychiatric issues. As a result, CB1 antagonists primarily acting through 
peripheral mechanisms have been a focus of intense research in the past (Mackie et al., 2005).  
       Another area of application of CB1 antagonists is in treatment of ‘craving disorders”. CB1 
receptor activation has also been associated with the reward behavior that is seen with opioids. In 
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rats treated with heroin, treatment with CB1 antagonists decrease reinstatement (Solinas et al., 
2003). In CB1 knockout-mice, the rewarding properties of opioids are attenuated. Apart from the 
therapeutic role in opioid abuse, another potential therapeutic application of CB1 antagonism is 
for alcohol abuse. Blocking CB1 receptors via antagonists have shown to reduce alcohol 
consumption. CB1 receptors are also being investigated as a promising target for other drugs of 
abuse such as nicotine and in smoking cessation (Mackie et al., 2005). 
       Another therapeutic area of intense interest for CB1 agonists has been antinociception 
especially in treatment of inflammatory and neuropathic pain. The CB1 receptor is densely 
expressed in brain regions involved in perception and modulation of nociceptive information 
such as thalamus, amygdala, and midbrain periaqueductal grey matter and in the substantia 
nigrosa of spinal cord. Arachidonyl-2-chloroethylamide (ACEA), a selective agonist of the CB1 
receptor, has been shown to induce antinociceptive effects in rat models with inflammatory pain. 
The CB1 receptor agonists such as HU-210, ∆9-THC, R-(+)-WIN55,212-2 and anandamide show 
antinociceptive effects in animal models of acute thermal, anti-inflammatory and neuropathic 
pain. (Manzanares et al., 2006) 
Other potential areas where ligands of CB1 may be of therapeutic value include 
neurodegenerative disorders such as Parkinson’s disease and Alzheimer’s disease. In 
Alzheimer’s disease, agonists such as WIN55,212-2, ACEA and CBD inhibit tau protein hyper-
phosphorylation which is one of the main biomarkers for Alzheimer’s disease pathology. This 
effect was mediated by CB1 which causes down-regulation of inducible nitric oxide synthase 
(Aso et al., 2014).  
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CHAPTER 2 
Indole-2-Carboxamides as Allosteric Modulators of the CB1 
Receptor 
 
This is an adaptation of an article that appeared in an ACS publication. ACS has not endorsed the 
content of this adaptation or the context of its use. Part of this chapter has been incorporated 
from published material (Khurana, L., Ali, H.I., Olszewska, T., Ahn, K. H., Damaraju, A., 
Kendall, D.A., Lu, D. “Optimization of Chemical Functionalities of Indole-2-Carboxamides to 
Improve Allosteric Parameters of the Cannabinoid Receptor 1 (CB1).” Journal of Medicinal 
Chemistry 57(7) (2014): 3040-3052 (http://pubs.acs.org/doi/full/10.1021/jm5000112). 
Compound syntheses was done by collaborators from Dr. Dai Lu’s lab at Texas, A&M. 
2.1 Background 
This chapter describes the optimization of indole-2-carboxamides to generate analogs with 
improved allosteric parameters at the CB1 receptor. The compounds were synthesized to evaluate 
the impact of modifying chemical functionalities of the indole-2-carboxamide scaffold on 
parameters that define the affinity for binding to the receptor and efficacy of allosteric 
modulation at the receptor. Cannabinoid agonists have been a subject of intense research to 
develop therapeutics in many diseases that the CB1 receptor is involved. For example, ∆9-THC 
has been demonstrated to be an effective antinociceptive agent in animal models of 
neurodegenerative and inflammatory disease states (Guindon et al., 2009; Pryce et al., 
2012; Fagan et al., 2014). However, due to the global activation of CB1 receptors in the brain and 
periphery by these ligands, these agonists pose side effects such as substance abuse, dependence 
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and impaired memory (Justinova et al, 2003; Cooper et al., 2009). However, endogenous ligands 
are synthesized on demand and metabolize easily and thus may have lesser side effects (Dimarzo 
et al., 1999; Ignatowska-Jankowska et al., 2015). PAMs of the CB1 receptor, thus offer the 
potential to alter the endogenous signaling without generating the side effects posed by other 
cannabinoid-based therapeutics. Here, we have identified some PAMs of CB1 receptor. These 
allosteric modulators demonstrated biased agonism for β-arrestin 1 mediated pathways. Thus, 
these allosteric modulators hold promise to develop therapeutics which are not only subtype-
specific but also pathway specific. 
 
2.2 Introduction 
The CB1 receptor is the most abundant GPCR expressed in the CNS (CNS), where it 
attenuates the release of excitatory and inhibitory neurotransmitters (Howlett et al., 2004; Mackie 
et al., 2008; Mackie et al., 2008).	The CB1 receptor is also present in lower concentrations in a 
variety of peripheral tissues, including, spleen, tonsil, gastrointestinal tract, liver, kidney, and 
heart (Gerard et al., 1991; Straiker et al., 1999; Galiegue et al., 1995). It regulates a variety of 
physiological functions including neuronal development, neuromodulatory processes, 
metabolism, nociception, and cardiovascular as well as reproductive functions (Howlett et al., 
2004; Pertwee et al., 2006; Mackie et al., 2006). While CB1 preferentially couples to Gi/o type G 
proteins, it can interact with Gs (Glass et al., 1997) or Gq (Lauckner et al., 2005) under some 
conditions. The CB1 receptor also modulates the activation of mitogen-activated protein kinases 
(MAPKs)	(Turu et al., 2010), inhibits N- and P/Q-type voltage-gated Ca2+ channels, activates A-
type and inwardly rectifying K+ channels (Howlett et al., 2005). Moreover, the CB1 receptor can 
interact with non-G protein partners such as β-arrestins, adaptor protein AP-3, GPCR-associated 
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sorting protein 1 (GASP1) and the adaptor protein FAN to control receptor signaling or 
trafficking (Howlett et al., 2010; Smith et al., 2010). The complex signaling network of the CB1 
receptor suggests the existence of finely-controlled modulatory mechanisms of receptor 
functions.  
Traditionally, the functions of the CB1 receptor is regulated through various agonists, 
partial agonists, antagonists and inverse agonists (Pertwee et al., 2006), which bind to the 
orthosteric site where the endogenous cannabinoids bind. Recently, several allosteric modulators 
of the CB1 receptor have been identified, which bind to sites that are topologically distinct from 
the orthosteric binding site. These include 5-chloro-3-ethyl-N-(4-(piperidin-1-yl)phenethyl)-1H-
indole-2-carboxamide (1, ORG27569) (Price et al., 2005), 1-(4-chlorophenyl)-3-(3-(6-
(pyrrolidin-1-yl)pyridin-2-yl)phenyl)urea (PSNCBAM-1) (Horsewill et al., 2007), 3-(4-
chlorophenyl)-5-(8-methyl-3-p-tolyl-8-azabicyclo[3.2.1]octan-2-yl)isoxazole (RTI-371)	
(Navarro et al., 2009) and the endogenous ligand (5S,6R,9E,11Z,13E,15S)-5,6,15-
trihydroxyicosa-9,11,13-trienoic acid (lipoxin A4) (Pamplona et al., 2012).  Allosteric 
modulators typically work cooperatively with orthosteric ligands and stabilize the receptor in 
various biological conformations that may be difficult to achieve by the orthosteric ligands 
(Wang et al., 2013). This increases the possibility of regulating receptor activities in more 
sophisticated ways than with orthosteric ligands. Thus, allosteric modulation can significantly 
expand the pharmacological repertoire for a given receptor (Wootten et al., 2013; Gao et al., 
2013). Additionally, allosteric sites are less structurally conserved than the corresponding 
orthosteric site and thus provide new opportunities for the development of more selective 
therapeutics (Mackie et al., 2006; Christopoulos et al., 2002). The discovery of CB1 allosteric 
modulators lays the foundation for receptor-selective and signaling-pathway-selective therapies.  
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Compound 1 was the first allosteric modulator identified for the CB1 receptor (Price et 
al., 2005). It augments specific binding of the CB1 agonist 2-[(1R,2R,5R)-5-hydroxy-2-(3-
hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl)phenol ([3H]CP55,940) but decreases the 
binding of the  inverse agonist 5-(4-Chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-N-
(piperidin-1-yl)-1H-pyrazole-3-carboxamide ([3H]SR141716A) in membranes from cells 
expressing the CB1 receptor (Price et al., 2005; Ahn et al., 2012).	 Despite acting as an enhancer 
of agonist binding, it antagonizes agonist-induced G- protein coupling to the receptor (Price et 
al., 2005; Ahn et al., 2012). It was further demonstrated that 1 in the absence of any orthosteric 
agonist can induce cellular internalization of the CB1 receptor and downstream activation of 
ERK signaling mediated by β-arrestins (Ahn et al., 2012; Ahn et al., 2013; Baillie et al., 2013), 
as a consequence of CB1 receptor activation. This indicates that allosteric modulators of the CB1 
receptor offer the potential to develop drugs capable of generating therapeutic effects via ligand-
biased signaling pathways.  
Following the discovery of 1 (Price et al., 2005), structure activity relationship (SAR) 
studies have revealed that the indole-2-carboxamide scaffold is a viable template for developing 
CB1 allosteric modulators (Ahn et al., 2013; Piscitelli et al., 2012; Mahmoud et al., 2013). The 
general structure of this class of compounds can be divided into two moieties comprising the 
bicyclic aryl fragment and the amide fragment (Figure 2.1). 
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Figure 2.1 Compound 1 and general structure of indole-2-carboxamides.	
        Earlier results from us (Ahn et al., 2013; Mahmoud et al., 2013) and others (Piscitelli et al., 
2012) have identified several key SARs within this class of compounds (I). These include 1) the 
indole ring of I (Figure 2.1) impacts the ligand’s capability to bind to the allosteric site more than 
the ligand’s capability to modulate the orthosteric site (Mahmoud et al., 2013); 2) the presence of 
a linear alkyl group at the C3 position of the indole ring is instrumental and its length has a 
profound influence on the allosteric modulation of the orthosteric binding site (Ahn et al., 2013; 
Mahmoud et al., 2013);  3) the amide functionality at the C2 position of the indole ring  is critical 
for the allosteric effects on the orthosteric site (Piscitelli et al., 2012); 4) shortening the linker 
between the amide bond and the phenyl ring B abolished the allosteric modulation of the 
orthosteric binding site (Mahmoud et al., 2013); 5) replacing the piperizinyl group of 1 with 
various functional groups (Piscitelli et al., 2012; Mahmoud et al., 2013) generally led to reduced 
allosteric modulation except  for the methylamino (Piscitelli et al., 2012)  and dimethylamino 
groups (Piscitelli et al., 2012; Mahmoud et al., 2013). Along with 1, a few other indole-2-
carboxamides (Price et al., 2005; Ahn et al., 2013; Piscitelli et al., 2012) have also shown 
allosteric modulation of the CB1 receptor. These molecules 5-chloro-3-pentyl-N-(4-(piperidin-1-
yl)phenethyl)-1H-indole-2-carboxamide (2, ICAM-b)	 (Ahn et al., 2013), N-(4-
(dimethylamino)phenethyl)-3-ethyl-5-fluoro-1H-indole-2-carboxamide (3, ORG27759) (Price et 
al., 2005), 5-chloro-N-(4-(dimethylamino)phenethyl)-3-ethyl-1H-indole-2-carboxamide (4)	
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(Piscitelli et al., 2012) and 5-chloro-N-(4-(dimethylamino)phenethyl)-3-pentyl-1H-indole-2-
carboxamide (5) (Mahmoud et al., 2013) are shown in Figure 2.2. KB and α values for some of 
these compounds is shown in Table 2.1. 
	
Figure 2.2 Representative indole-2-carboxamides showing CB1 allostery. 
In this context, we expanded our SAR studies of indole-2-carboxamides. Our efforts 
include elongation of the linker between the amide bond and the phenyl ring B, further 
investigation of the requirement of the C3 alkyl group (i.e. R1) and modification of the 
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substitutions (i.e. R2) on the phenyl ring A of the bicyclic aryl fragment. To date, most of the 
reported indole-2-caboxamides showing CB1 allostery was developed from a 5-chloro-indole-2-
carboxamide template (Price et al., 2005; Ahn et al., 2013; Piscitelli et al., 2012; Mahmoud et al., 
2013) except 3 (Price et al., 2005). Hence, we investigated the impact of different substitutions 
of the phenyl ring A (Figure 2.1) on the allosteric effects. This effort led to the compounds 21a-d 
(Table 2). The allosteric effects of these compounds are evaluated by two essential parameters 
(Christopoulos et al., 2002; May et al., 2007): the equilibrium dissociation constant (KB), which 
reflects the binding affinity of the ligands to the allosteric site, and the binding cooperativity 
factor (α) that denotes the allosteric interaction between the orthosteric and allosteric ligands 
when they both occupy the receptor, i.e. it quantifies the direction of and magnitude by which the 
affinity of one ligand is changed by the other ligand when both are bound to the receptor to form 
the ternary complex (Christopoulos et al., 2004). When α is 1.0, the test modulator does not alter 
orthosteric ligand binding. If α is less than 1.0, the test modulator reduces orthosteric ligand 
binding (negative allosteric modulation of orthosteric ligand binding). If α is greater than 1.0, the 
modulator increases orthosteric ligand binding (positive allosteric modulation of orthosteric 
ligand binding) (Christopoulos et al., 2002). The α and KB values were analyzed according to the 
allosteric ternary complex model (Price et al., 2005). Selected allosteric modulators were 
assessed for their effects on agonist-induced G-protein coupling activity and β-arrestin mediated 
ERK1/2 phosphorylation.  
 
Chemistry 
Dr Dai Lu’s lab used the following procedures to carry out the chemical synthesis of compounds 
12a-f, 21a-d and 26: 
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The syntheses of C3-alkylated indole-2-carboxamides (12a-f) were achieved through the 
methods illustrated in Figure 2.3. The C3 substituents were introduced through Friedel-Crafts 
acylation of the ethyl 5-chloroindole-2-carboxylate (6), which is commercially available. 
Acylation of 6 with various selected acyl chlorides (7a-c) provided the desired 3-acyl-5-
chloroindole-2-carboxylates (8a-c). Reduction of their ketone groups by triethylsilane generated 
the C3 alkylated 5-chloroindole-2-carboxylates (9a-c), which were then hydrolyzed in basic 
conditions to yield the key intermediate indole-2-carboxylic acids (10a-c). The final compounds 
(12a-f) were prepared by coupling commercially available amines (11a-b) with the acids (10a-c) 
individually in the presence of BOP and diisopropylethyl amine (DIPEA) in anhydrous DMF at 
room temperature. 
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Figure 2.3 Synthesis of 3-alkyl-5-chloroindole-2-carboxamides 12a-f. Reagents and Conditions: 
(i) AlCl3, 1,2-dichloromethane, reflux, 2-3 h; (ii) (Et)3SiH, CF3COOH, 0°C-rt, 4-12 h; (iii) 3N 
NaOH, EtOH, reflux, 2 h; (iv) BOP, DIPEA, DMF, rt, 4-12 h. 
 
To access the indole-2-carboxamides with different substituents on the phenyl ring A 
(21a-d), we employed Hemetsberger-Knittel indole synthesis (Hemetsberger et al., 1972), by 
which the required indole-2-carboxylate 17 can be obtained through Knoevenagel	condensation 
of methyl 2-azidoacetate 14 with the substituted benzaldehyde 15 followed by a thermolysis of 
the azide of the resultant methyl-2-azidocinnamate 16 and an electrophilic cyclization. The 
synthesis of indole-2-carboxylate 17 through Hemetsberger-Knittel reaction depends on the 
reaction conditions, which include the reaction temperature and stoichiometry of reactants in the 
Knoevenagel	 condensation (step ii, Figure 2.4) and the concentration of reactant in the 
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subsequent thermolytic cyclization (step iii, Figure 2.4). We optimized the reaction conditions to 
obtain 16 and 17 in good yield to proceed with the synthesis .  The cyclization of 16d provided 
two regioisomers the 5- and 7-substituted indole-2-carboxylates (17d and 17e) with the 5-
regioisomer (17d) being slightly favored over the 7-regioisomer (17e). The structures of the two 
regioisomers were assigned by comparison of their 1H NMR with the reported data (Yamazaki et 
al., 2003; Vieira et al., 2008). Acylation of 17a-17d by Friedel-crafts reaction led to the major 
product as the desired 3-acyl-indol-2-carboxylates 18a-18d. However, acylation of 17e generated 
the 4-acyl-indole-2-carboxamide as the major product, which is not suitable for SAR study in 
this series; hence, the 4-acylated product was not further pursued in the synthesis of 
corresponding indole-2-carboxamide 21. Following the preparation of 3-acylated indole-2-
carboxylates 18a-18d, we synthesized the corresponding final products 21a-21d by following 
Figure 2.3 (steps i-iv). 
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Figure 2.4 Synthesis of 3-ethyl indole-2-carboxamides 21a-d. Reagents and Conditions: (i) 
NaN3, DMF, rt, 1.5 h; (ii) NaOCH3/CH3OH, −20 °C, 5 h; (iii) xylene, reflux, 3 h; (iv) AlCl3, 1,2-
dichloromethane, reflux, 2.5 h; (v) (Et)3SiH, CF3COOH, 0 °C-rt, 4 h; (vi)  3 N NaOH, EtOH, 
reflux, 2 h; (vii) BOP, DIPEA, DMF, rt, 4-12 h. 
 
The indole-2-carboxamide 26 was synthesized according to the route illustrated in Figure 
2.5. It was prepared through coupling of 4-(3-aminopropyl)-N,N-dimethyl aniline  24 with 5-
chloro-3-ethyl-1H-indole-2-carboxylic acid 25, which was synthesized according to the reported 
method (Mahmoud et al., 2013). For the synthesis of 24, 4-dimethylaminobenzaldehyde 22 was 
condensed with acetonitrile through aldol condensation in strong basic conditions to yield a 
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mixture of (E)- and (Z)-3-(4-(dimethylamino)phenyl)acrylonitrile 23 which was reduced to yield 
amine 24. 
 
 
 
 
 
 
 
 
 
Figure 2.5 Synthesis of indole-2-carboxamide 26. Reagents and Conditions: (i) CH3CN, KOH, 
reflux, 10 min; (ii) THF, LiAlH4, AlCl3, reflux, 1 h; (iii) BOP, DIPEA, DMF, rt, 4-12 h. 
  
2.3 Materials and Methods  
Compounds. Tested compounds (12a-12f and 21a-21d) were synthesized for this study except 
1, which was purchased from Tocris Bioscience (Minneapolis, MN). Compounds 2 (Ahn et al., 
2013) and 12g, 12h and 5 have previously been reported by us (Mahmoud et al., 2013) and were 
cited in this report for comparison. Compound 4 was earlier reported (Piscitelli et al., 2012), and 
was resynthesized and tested in our laboratories for comparative purposes. 
CB1 Expression and membrane preparation. HEK 293 cells were maintained in Dulbecco’s 
modified Eagle’s medium supplemented with 10% fetal bovine serum and 3.5% mg/ml glucose 
at 37ºC in 5% CO2. One day prior to transfection, cells were seeded at approximately 900,000 
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cells/100 mm dishes. The cells were transiently transfected by the calcium phosphate 
precipitation method (Chen et al., 1987).  At 24h post transfection, the cells were harvested and 
washed twice with phosphate buffered saline (PBS). The cells were resuspended in PBS solution 
containing mammalian protease inhibitor cocktail ((4-2-aminoethyl) benzene-sulfonyl fluoride, 
pepstatin A, E-64, bestatin, leupeptin, and aprotinin) (Sigma-Aldrich, St. Louis, MO) and lysed 
by nitrogen cavitation at 750 psi for 5 min using a Parr cell disruption bomb. The lysate was 
spun at 500 g for 10 min at 4ºC and the supernatant was subsequently spun at 100,000 g for 45 
min at 4ºC. The membrane-containing pellet was resuspended in TME buffer (25 mM Tris-HCl, 
5 mM MgCl2, and 1 mM EDTA, pH 7.4) containing 7% w/v sucrose. For immunoblotting 
studies, HEK 293 cells were transfected using lipofectamine (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s instructions. 24 hr post-transfection, cells were washed and 
incubated for an additional 18 h in serum-free growth media. siRNA transfection was carried out 
as previously described (Ahn et al., 2013). Briefly, HEK293 cells in a 6-well plate were 
transfected with the plasmid encoding CB1 and 2.6 micrograms of siRNA (Qiagen, Valencia, 
CA) targeting β-arrestin 1 or non-silencing RNA duplex for control. 
Radioligand binding assay. Ligand binding assays were performed as previously described to 
determine the cooperativity between the orthosteric and allosteric ligands (Ahn et al., 2012). 
Briefly, 6µg of membrane preparation was incubated for 60 min with a fixed concentration of 
tracer [3H]CP55940 (141 Ci/mmol, PerkinElmer Life Sciences (Boston, MA)) typically at its Kd 
which was determined from a saturation binding isotherm in a total volume of 200 µL of TME 
buffer containing 0.1% fatty acid-free BSA. Ligand depletion was avoided by adjusting the 
amount of membrane sample and total assay volume to keep the bound ligand less than 10% of 
the total. At least nine concentrations of unlabeled test compound (ranging between 100 pM and 
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100 µM) were used for the binding assays as described previously (Ahn et al., 2012). 
Nonspecific binding was determined in the presence of unlabeled CP55,940 (1 µM). The 
reaction was terminated by addition of 250 µL TME buffer containing 5% BSA followed by 
filtration with a Brandel cell harvester through Whatman GF/C filter paper followed by washing 
with ice cold TME buffer. Radioactivity was measured using liquid scintillation counting. 
GTPγS Binding Assay. GTPγS binding assays were performed as described previously (Ahn et 
al., 2012). Briefly, 7.5 µg of membranes were incubated for 60 min at 30°C in a total volume of 
200 µL GTPγS binding assay buffer (50 mM Tris-HCl, pH 7.4, 3 mM MgCl2, 0.2 mM EGTA, 
and 100 mM NaCl) with unlabeled CP55,940 (at least nine different concentrations were used 
ranging between 100 pM and 100 µM), 0.1 nM [35S]GTPγS (1250 Ci/mmol; PerkinElmer Life 
Sciences, Boston, MA), 10 µM GDP (Sigma, St. Louis, MO), and 0.1% (w/v) BSA in the 
absence and presence of varying concentrations of the allosteric compounds as indicated. 
Nonspecific binding was determined with 10 µM unlabeled GTPγS (Sigma, St. Louis, MO). The 
reaction was terminated by rapid filtration through Whatman GF/C filters. The radioactivity 
trapped in the filters was determined by liquid scintillation counting.  
Ligand and GTPγS Binding Data Analysis.  All ligand binding assays were carried out in 
duplicate. Data are presented as the mean ± S.E. or the mean with the corresponding 95% 
confidence limits from at least three independent experiments. The interactions between the 
orthosteric radiolabeled agonist [3H]CP55,940 and the test modulators were analyzed by 
nonlinear regression using Prism 6.0 (Graphpad Software Inc., San Diego, CA) as previously 
described (Ahn et al., 2012).  
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Immunoblotting Studies. Cells expressing the CB1 receptor and siRNA targeting β-arrestin 1 or 
non-silencing RNA duplex were washed twice with PBS and exposed to varying concentrations 
of allosteric modulators (2, 12d or 12f) in the presence of 0.2 µM CP55,940 for 5 min. To 
observe the effect of the modulators on pertussis toxin (PTX)-insensitive ERK1/2 
phosphorylation, cells were treated with 5 ng/ml PTX for 16 h at 37 °C prior to compound 
treatment. The media were aspirated and the cells were washed with ice-cold PBS and lysed in 
ice-cold lysis buffer (150 mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium deoxycholate, 0.1% 
SDS, 50 mM Tris, pH 7.5) and a protease inhibitor cocktail (4-(2-aminoethyl)benzenesulfonyl 
fluoride (AEBSF), pepstatin A, E-64, bestatin, leupeptin, and aprotinin; Sigma, St Louis, MO). 
Solubilized cell extracts were centrifuged at 18,500 g for 15 min at 4 °C and the supernatant was 
transferred to a new tube and heated at 95°C for 3 minutes. 12 µg of total protein was resolved 
by 10% SDS-PAGE, and transferred to polyvinylidene fluoride (PVDF) membrane. After 
washing with blocking reagent (Fisher Scientific, Pittsburgh, PA), the membrane was incubated 
for 1h at rt with the primary antibody (1:3000 phospho-p44/42 and p44/42 antibodies; Cell 
Signaling Technology, Danvers, MA). After washing with PBS, the membrane was incubated 
with anti-rabbit peroxidase-conjugated secondary antibody (1:5000; Cell Signaling Technology, 
Danvers, MA) for 60 min at rt. Immunoreactivity was visualized and quantified as reported 
earlier (Ahn et al., 2013).  
Synthesis. All chemical reagents and solvents were purchased from Sigma-Aldrich Chemical 
Company unless specified otherwise and used without further purification. All anhydrous 
reactions were performed under a static argon atmosphere in dried glassware using anhydrous 
solvents. Organic phases in the work up were dried over anhydrous Na2SO4, and removed by 
evaporation under reduced pressure. The crude compounds were purified by a Combiflash Rf 
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chromatography system (Teledyne Technologies, Inc, Thousand Oaks, CA) unless specified 
otherwise. Purities of the intermediates were established by Thin-layer Chromatography (TLC), 
melting point, 1H NMR, and mass spectrometry. Analytical Thin-layer Chromatography (TLC) 
was run on pre-coated silica gel TLC aluminum plates (Whatman®, UV254, layer thickness 250 
µm), and the chromatograms were visualized under ultraviolet (UV) light. Melting points were 
determined on a capillary Electrothermal® melting point apparatus and are uncorrected. 1H 
NMR spectra of intermediates were recorded on a Bruker Avance DPX-300 spectrometer 
operating at 300 MHz. 1H NMR spectra of the final compounds were recorded on a Bruker AV-
500 spectrometer operating at 500 MHz. All NMR spectra were recorded using CDCl3 or 
DMSO-d6 as solvent unless otherwise stated and chemical shifts are reported in ppm (parts per 
million) relative to tetramethylsilane (TMS) as an internal standard. Multiplicities are indicated 
as br (broadened), s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), bs (broadened 
singlet) and coupling constants (J) are reported in hertz (Hz). Low resolution mass spectra were 
performed at the School of Chemical Sciences, University of Illinois at Urbana-Champaign. The 
purity of each tested compound was analyzed by combustion elemental analysis and was 
confirmed to be greater than 99%. (Roberson Microlit laboratories, Madison, NJ).  
The hemesberger-knittel reaction. The hemesberger-knittel reaction (step ii and iii, Figure 2.4) 
is postulated to proceed via a highly electrophilic singlet nitrene species, which then inserts into 
the phenyl ring to form the indole derivatives (Hemetsberger et al., 1972; Hemetsberger et al., 
1969; O’Brien et al., 2011). In some circumstances, the Knoevenagel condensation (step ii, 
Figure 2.4) requires highly excessive quantities of the reactant azidoacetate and the catalytic base 
(e.g. benzaldehyde:azidoacetate:methoxide = 1:10:10 molar ratio) to achieve high yields (Condie 
et al., 2005). We tried different stoichiometries of the reactants in the condensation of 14 with 15 
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and found when the molar ratio of reactants (benzaldehyde:azidoacetate:methoxide) is 1:3:3, it 
provided an acceptable yield ranging from 58% to 74% for the products 16a-d. When the molar 
ratio of reactants used was benzaldehyde:azidoacetate:methoxide = 1:10:10, the yields for 16a 
and 16b were increased from 59% and 58% to 93% (16a) and 69.6% (16b), respectively. 
Additionally, the yield of the 2-azidocinnamate from the Knoevenagel condensation also 
depends on the reaction temperature (Murakami et al., 1997). We found that optimal yields can 
be obtained when the reaction was firstly carried out at -20°C for 30 minutes and then at -5-0°C 
for 6-19 h (depending on the benzaldehyde employed). To obtain the indole-2-carboxylates 17 
via thermolytic cyclization of 16 (step iii, Figure 2.4), there are many thermolysis conditions 
reported, which include carrying the reaction with microwave and flow chemistry facilitated 
thermolytic cyclization (Lehmanna et al., 2009; O’Brien et al., 2011; Ranasinghe et al., 2013), 
and employment of various catalysts to facilitate the indole ring formation ( Stokes et al., 2007; 
Bonnamour et al., 2011). We tried various conditions including carrying the thermolytic reaction 
in different solvents such as regular xylene, anhydrous xylene, anhydrous toluene, and anhydrous 
THF heated in a pressure tube, as well as using iron (II) triflate to catalyze the reaction in THF 
(Bonnamour et al., 2011). We found that carrying the reaction in dilute and freshly prepared 
anhydrous xylene solution (i.e. 1 g of azidocinnamate 16 in ~100 mL xylene, approximately 40 
mM) for 30 minutes generally led to good yield of the products (88.6-94.6%) except 17b (53%).  
Specific details of synthesis of each compound can be found in the original publication. 
2.4 Results and Discussion 
Our previous investigations revealed that structural variation at the C3 position of indole-
2-carboxamide has a profound influence on CB1 allostery. We found that the C3 position prefers 
a linear alkyl group (Mahmoud et al., 2013). When the C3 ethyl group of 1 was replaced with a 
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n-pentyl group (2), it led to the enhancement of the allosteric effect, which is reflected by an 
improvement in the cooperativity factor α from 6.9 (1) to 17.6 (2) (Ahn et al., 2013). However, 
further increasing the length of the C3 alkyl to n-heptyl (12g (LDK1218)) and n-nonyl (12h 
(LDK1219)) groups did not improve the allosteric effects on CB1 (Mahmoud et al., 2013). Here, 
we elaborated our investigation of the C3 position with variations of the linear alkyl groups such 
as n-propyl, n-butyl and n-hexyl groups. The allosteric parameters of the analogs are presented in 
Table 2.1. The results reflect that a specific length of the linear alkyl group is required at the C3 
position. Increasing the length of the C3 alkyl group of 1 to n-propyl (12a (LDK1259)), n-butyl 
(12b (LDK1260)) and n-pentyl (2) led to the significant enhancement of binding cooperativity 
(α).  When the length was further elongated to n-hexyl (12c (LDK1261)), n-heptyl (12g 
(LDK1218)) and n-nonyl (12h (LDK1219)), the binding cooperativity (α) decreased to a level 
comparable to 1. Notably, the significant increase of the binding cooperativity factor (α) of 12a 
(LDK1259) and 12b (LDK1260) was accompanied by reduced binding affinities to the allosteric 
site. This reflects that an allosteric modulator can induce a receptor conformation that enhances 
orthosteric ligand binding despite having a relatively low affinity for the allosteric site. As has 
been shown previously, the affinity of an allosteric modulator (KB) and the allostery (α) it 
exhibits for the orthosteric compound are not necessarily correlated (Christopoulos et al., 1999; 
May et al., 2005). In this series of modifications (entry 1-7, Table 2.1), the C3 n-propyl provided 
markedly enhanced allosteric modulation of the orthosteric site (binding cooperativity factor α = 
26.7). We further assessed the effects of the length of C3 alkyl chain on allosteric properties 
using 4 as a scaffold because replacing the N-piperidinyl group of 1 with a dimethylamino group 
resulted in improvement of the allosteric effects of indole-2-carboxamides (Piscitelli et al., 2012; 
Mahmoud et al., 2013). This effort led to the analogs 12d-f with improved allosteric parameters. 
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The results suggest that the dimethylamino group on the phenyl ring B is superior to the N-
piperidinyl group of the indole-2-carboxamides yielding modulators with higher binding affinity 
for the allosteric site and greater cooperativity to the orthosteric site (e.g. 12d (LDK1256) vs 12a 
(LDK1259), 12e (LDK1257) vs 12b (LDK1260), 5 vs 2, and 4 vs 1, Table 2.1). Strikingly, the 
n-hexyl substituent (12f (LDK1258)) improved the equilibrium dissociation constant (KB) to 
89.1 nM with an α comparable to 1. Binding curves for compounds 12a-1f are shown in Figure 
2.6. 
Table 2.1 Allostery of indole-2-carboxamides 12a-f and some referenced compounds. 
 
 
 
Entry Compd R1 R2 KB (nM)a αb 
1 1c C2H5 N-piperidinyl 217.3 (170.3-277.2) 6.9 
2 12a (LDK1259) n-C3H7 N-piperidinyl 1746 (377.8-8065) 26.7 
3 12b (LDK1260) n-C4H9 N-piperidinyl 1985 (775.1-5082) 17.7 
4 2d n-C5H11 N-piperidinyl 469.9 (126.2-1750) 17.6 
5 12c (LDK1261) n-C6H13 N-piperidinyl 310.6 (110.5-873.2) 4.6 
6 12ge (LDK1218) n-C7H15 N-piperidinyl 651.2 (81.51-5203) 7.4 
7 12he (LDK1219) n-C9H19 N-piperidinyl 259.7 (87.56- 770) 6.8 
8 4e C2H5 N(CH3)2 207.4 (155.9-2759)     19.7 
9 12d (LDK1256) n-C3H7 N(CH3)2 259.3 (19.8-3365) 24.5 
10 12e (LDK1257) n-C4H9 N(CH3)2 209.0 (62.7--696.7) 12.8 
11 5 e n-C5H11 N(CH3)2 167.3 (23.39-1197) 16.5 
12 12f (LDK1258) n-C6H13 N(CH3)2 89.1 (47.08-168.4) 5.1 
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aKB: equilibrium dissociation constant of a potential allosteric ligand. bα: binding cooperativity 
factor for the tested allosteric modulator. Both parameters were tested using [3H]CP55,940 as the 
orthosteric ligand.  c Data cited for 1 are from our earlier report (Ahn et al., 2012) and are given 
for comparison. dData cited for 2 are from our earlier report (Ahn et al., 2013) and are given for 
comparison. eData cited for compounds 4, 5, 12g and 12h (LDK1219) are from our earlier 
report (Mariam et al., 2013) and are given for comparison. 
 
Table 2.2 Allostery of indole-2-carboxamides 21a-d and 26. 
                                     
 
									
	
Entry Compd R1 R2 n KB (nM)a αb 
13 4c Cl H      1 207.4 (155.9-2759)    19.7 
14 21a (LDK1265) H Cl 1 3673 (1048-12880) 16.0 
15 21b (LDK1266) H F 1 1580 (328.7-7599) 22.9 
16 21c (LDK1269) OCH3 H 1 2708 (973.4-7535) 6.2 
17 21d (LDK1264) H OCH3 1 4084 (1213-13750) 11.9 
18 26 (LDK1257)  Cl H      2           NDd NDd 
aKB: equilibrium dissociation constant of a potential allosteric ligand. bα: binding cooperativity 
factor for the tested allosteric modulator. Both parameters were tested using [3H]CP55,940 as the 
orthosteric ligand.  c Data cited for 4 are from our earlier report	 (Mariam et al., 2013) and are 
given for comparison. dND: no detectable modulation of [3H]CP55,940 binding using up to 32 
µM of test compound. 
The indole-2-caboxamide 4 (Piscitelli et al., 2012; Mahmoud et al., 2013) was used as a 
reference compound to vary the substitutions (Table 2.2) on the phenyl ring A (Figure 2.1). The 
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C5-chloro group of 4 is an electron withdrawing group (EWG) inductively and is electron 
donating by resonance. To evaluate the impact of the substitution position, we moved the C5-
chloro group of 4 to the C6 position. This modification (21a (LDK1265)) drastically reduced the 
binding affinity to the allosteric site (KB = 3673 nM), but not the allosteric modulation of the 
orthosteric ligand binding (α = 16.0). Because a fluoro group has a greater electron-withdrawing 
inductive effect than a chloro group, we replaced the C6-chloro group with a C6-fluoro group 
(21b (LDK1266)), this modification did not improve the binding affinity to the allosteric site 
(KB = 1580 nM) while the allosteric modulation on orthosteric ligand binding is well preserved 
(α = 22.9) in comparison with 4 (α = 19.7). The result from 21b (LDK1266) along with an 
earlier result of 3, which is a 5-fluro-indole-2-carboxamide (Price et al., 2005), suggested that 
fluoro as a substituent on ring A is suboptimal than a chloro group. Taken the fact that chloro 
group is an EWG inductively and is electron donating group (EDG) by resonance, we replaced it 
with a methoxy group, which is purely an EDG. This modification led to 21c (LDK1269), which 
exhibited a significantly decreased cooperativity factor (α = 6.2) and the binding affinity (KB = 
2708 nM) in comparison with 4 (α = 19.7, KB = 207.4 nM). Moving the methoxy group to the 
C6-position (21d (LDK1264)) also reduced the allosteric effect on the orthosteric site and the 
binding affinity to the allosteric site. This series of compounds (entry 13-17) suggested that the 
nature and the position of the substituent on the phenyl ring A are critical for both the binding 
affinity (KB) to the allosteric site and the binding cooperativity with the orthosteric site.  Binding 
curves for the compounds 21a-21d and 26 are shown in Figure 2.7. 
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Figure 2.6 Binding curves for analogs 12a-12f. The binding curves show the impact of varying 
concentrations of test compounds 12a (A), 12b (B), 12c (C), 12d (D), 12e (E) and 12f (F) on the 
binding of [3H]CP55,940. 
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Figure 2.7 Binding curves for analogs 21a-21d and 26. The binding curves show the impact of 
varying concentrations of test compounds 21a (A), 21b (B), 21c (C), 21d (D) and 26 (E) on the 
binding of [3H]CP55,940. 
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In line with our earlier finding that the one carbon linker between the amide bond and the 
phenyl ring B (Figure 2.1) abolished the allostery of this class of compounds on CB1 receptor 
(Mahmoud et al., 2013), the loss of allosteric modulation of orthosteric agonist CP55,940 
binding with 26 (LDK1257) indicated the critical role of the 2-carbon linker between the amide 
bond and the phenyl ring B of the amide fragment within the structure of indole-2-carboxamides 
(I, Figure 2.1).  
The two robust allosteric modulators 12d (LDK1256) and 12f (LDK1258) were further 
tested for their effect on CP55,940-induced G-protein coupling activity. It was found that both 
the compounds showed a concentration-dependent inhibition of agonist-induced GTPγS binding 
as shown in Figure 2.8 
 
 
 
. 
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Figure 2.8 Dose−response curves for CP55,940-induced [35S]GTPγS binding to HEK293 cell 
membranes expressing the CB1 receptor in the absence and presence of compounds 12d 
(LDK1256) (A) and 12f (LDK1258) (B) at the indicated concentrations. Nonspecific binding 
was determined in the presence of 10 µM unlabeled GTPγS. Data is presented as specific binding 
of GTPγS (fmol/mg) to the membranes. Each data point represents the mean ± S.E. (error bars) 
of at least three independent experiments performed in duplicate. 
We previously demonstrated that ERK1/2 can be activated via CB1 in a G-protein-
dependent manner by CP55,940 alone and a G-protein-independent manner in the presence of 1 
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or 2 and CP55,940 (Ahn et al., 2012; Ahn et al., 2013; Ahn et al. 2013). In agreement, 
CP55,940-induced ERK1/2 phosphorylation was substantially attenuated by pertussis toxin 
(PTX) but not by β-arrestin knockdown indicating alone it is Gi-protein mediated (Figure 2.9A). 
In contrast, yet in-line with the observed inhibition of G protein coupling activity (Figure 2.8), 
ERK1/2 phosphorylation due to 12f (LDK1258) treatment was PTX insensitive (Figure 2.9A) 
suggesting utilization of a β-arrestin mediated pathway. Furthermore, Figure 2.9B-D show that 
co-treatment of 2, 12d (LDK1256) or 12f (LDK1258) and CP55,940 induce concentration-
dependent ERK1/2 phosphorylation that is β-arrestin-1 sensitive; the β-arrestin 1 knockdown 
resulted in substantial inhibition of ERK1/2 phosphorylation induced by 2, 12d (LDK1256) and 
12f (LDK1258). These results indicate that 2, 12d (LDK1256) and 12f (LDK1258) are 
functionally positive allosteric modulators, at least for ERK1/2 phosphorylation. Interestingly, 
12d (LDK1256) and 12f (LDK1258) reached a plateau at 5 µM of the modulator whereas 2 
required 10 µM to achieve comparable levels of ERK1/2 phosphorylation (Figure 2.9E). This 
may reflect the higher binding affinity of 12d (LDK1256) and 12f (LDK1258) relative to that of 
2 (Table 2.1).  
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Figure 2.9 Effect of 12d and 12f on ERK1/2 phosphorylation. (A) Mock-transfected and 
treatment conditions for CP55,940 (0.2 µM), PTX, and siRNA knockdown of HEK293 cells 
expressing CB1 are indicated and shown for comparison. (B-D) HEK293 cells expressing CB1 
receptors were exposed to 0, 0.05, 0.1, 0.5, 1, 5, 10 µM of 2 (B), of 12d (C) or of 12f (D) in the 
presence of 0.2 µM CP55,940 for 5 min with PTX pre-treatment for 16 hrs. Cell lysates were 
separated on SDS-PAGE and analyzed by western blots probed with phospho-ERK1/2 (p-
ERK1/2). The total level of ERK1/2 was detected for comparison. Note that the two bands 
correspond to the predominant isoforms, p42 (ERK2) and p44 (ERK1) for ERK1/2. (E) Graphs 
provide the quantified ERK1/2 phosphorylation levels induced by each compound for 5 min. 
Data represent the mean ± S.E. and are expressed as a percent of the level of CP55,940-induced 
ERK1/2 phosphorylation (Done by Kwang H. Ahn).  
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2.5 Conclusions and Future Directions 
The results from the newly synthesized indole-2-carboxamides along with our earlier findings	
(Mahmoud et al., 2013) elucidated key structural requirements of indole-2-carboxamides for 
allosteric modulation of the CB1 receptor. The critical structural factors include:  1) the chain 
length of the C3-alkyl group is critical with n-propyl being preferred for allosteric modulation of 
orthosteric ligand binding and n-hexyl being  preferred for enhancing affinity of the allosteric 
modulator to the CB1 receptor; 2) an electron withdrawing group needs to reside at the C5 
position of the indole ring; 3) the linker between the amide bond and the phenyl ring B must be 
an ethylene group whereas shortening or elongating the linker abolishes allosteric effects; and 4) 
the substituent on the phenyl ring B explicitly influences both the binding to the allosteric site 
and the binding cooperativity with the orthosteric ligand, with the N,N-dimethyl amino group 
being preferred over the piperidinyl functionality of the prototypical CB1 allosteric modulator 1. 
These SARs will guide the future design and synthesis of more potent CB1 allosteric modulators 
based on the indole-2-carboxamide scaffold. The therapeutic usefulness of CB1 allosteric 
modulators is becoming evident. For instance, the CB1 allosteric modulator PSNCBAM-1 
exhibits acute hypophagic effects (Horsewill et al., 2007) and antagonism of neuronal 
excitability (Wang et al., 2011), which have the potential for the treatment of obesity and some 
CNS disorders. The endogenous CB1 allosteric modulator Lipoxin A4 is capable of protecting 
neuronal cells from β-amyloid-induced neurotoxicity (Pamplona et al., 2012) that has been 
implied in the etiology of Alzheimer’s disease. Given the nature of biased signaling of some CB1 
allosteric modulators from the indole-2-carboxamide class, selective regulation of signaling-
pathway-specific functions of the CB1 receptor is possible and this may be therapeutically 
beneficial. The angiotensin II receptor, for example, may exhibit G-protein dependent or β-
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arrestin-dependent signaling. Biased agonism of this receptor to promote β-arrestin mediated 
effects only, may provide a beneficial cytoprotective response and obviate a deleterious increase 
in blood pressure that is observed in a G-protein manner (Kenakin et al., 2010). This offers 
tremendous opportunities for developing drugs for many disorders that have been linked to the 
CB1 receptor in the CNS and periphery. 
Further optimization of the allosteric modulators presented in this chapter to improve the binding 
affinity and cooperativity of these compounds will be useful for therapeutic purposes. It would 
be of great interest to utilize these compounds and evaluate their allosteric effects on 
endocannabinoids such as AEA and 2-AG. Such information will aid in providing more 
information about the pharmacological profile of these compounds.  
Also of interest will be to evaluate the impact of these compounds on other kinases such as 
JNK1/2/3. CREB, Akt and heat shock proteins. This will allow us to identify other signaling 
pathways that may be modulated by these allosteric modulators. Evaluation of these compounds 
in animal models to establish their therapeutic utility is also needed. Recent studies on 
ORG27569 in animal models demonstrated attenuation of cue- and drug-induced reinstatement 
of cocaine and methamphetamine. However, the involvement of CB1 receptor in these effects 
was not determined (Jing et al., 2014). This necessitates further studies of other allosteric 
modulators of CB1 receptor such as those shown in this chapter.  
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CHAPTER 3 
Pyrimidinyl Biphenylureas as Allosteric Modulators of CB1 receptor: 
Establishing Structure-Activity Relationships 
3.1 Background 
This chapter focuses on utilizing another scaffold, pyrimidinyl biphenylureas and 
modifying this scaffold to identify chemical groups important for allostery at the CB1 receptor. 
PSNCBAM-1, which has been previously reported as an allosteric modulator of CB1 with a 
diarylurea scaffold was modified by replacing the pyridine ring for a pyrimidine ring and two 
regioisomers were generated. Modifications were made with these regioisomers to introduce 
changes in the substituents on ring A of the scaffold (Figure 3.1) or modifications were made in 
the substituents on the pyrimidine ring to generate 30 different compounds, which were further 
evaluated for allostery at the CB1 receptor.  
Considerable interest has been generated in development of allosteric modulators of CB1 due to 
the many advantages posed by these over their orthosteric counterparts.  PSNCBAM-1 has been 
of particular interest due to its effects in acute food intake studies on rat models. PSNCBAM-1 
showed a decrease in cumulative food intake and overall change in the body weight, suggesting 
that this allosteric modulator can be used to develop anti-obesity drugs. CB1 receptor has been a 
target of intense research to develop anti-obesity drugs in the past. Rimonabant (also called 
SR141716A), an inverse agonist of CB1 has been previously marketed as an anti-obesity drug. 
However, it was withdrawn from the market to its psychiatric side effects. With PSNCBAM-1 
showing promise as an anti-obesity drug, these compounds synthesized by modifications in 
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PSNCBAM-1 may help generate therapeutics with anorexic effects. Recently, PSNCBAM-1 has 
also been investigated for its role in decreasing neuronal excitability. It was demonstrated that 
PSNCBAM-1 reduces CP55,940 induced neuronal excitability in cerebellum. This decrease in 
the excitability was not seen in the absence of CP55,940, thus exhibiting that no intrinsic 
changes to neuroexcitability occur with PSNCBAM-1 (Wang et al., 2011). This is an advantage 
of utilizing PSNCBAM-1 over CB1 orthosteric agonists which demonstrate intrinsic changes in 
neuronal excitation, which is undesirable as was seen with Rimonabant. Thus, these allosteric 
modulators can be alternative pharmacological agents for therapeutic modulation of CB1 
receptors in diseases of the CNS exhibiting cerebellar dysfunction.  
3.2 INTRODUCTION 
The endocannabinoid system (ECS) consists of two-well characterized receptor subtypes, the 
cannabinoid receptor 1 (CB1) and the cannabinoid receptor 2 (CB2), the eicosanoid ligands 
synthesized in the body called endocannabinoids and several metabolic proteins (e.g. fatty acid 
amide hydrolase, monoacylglycerol lipase) (Petrocellis et al., 2004). Both the receptors are 
activated by ∆9-tetrahydrocannabinol (THC), the psychoactive component of marijuana 
(Cannabis sativa) and belong to class 1A rhodopsin-like G-protein coupled receptors (GPCRs). 
Moreover, CB1 is one of the most abundant GPCRs expressed in the central nervous system 
(CNS) (Howlett et al., 2004; Mackie et al., 2008). Upon activation, the CB1 receptor primarily 
couples to Gi/o protein, which causes downstream inhibition of adenylyl cyclase.  The CB1 
receptor can also activates inwardly rectifying and A-type outward potassium channels (Mackie 
et al., 1995; Mu et al., 1999) and inhibit N-type and P/Q type of calcium channels (Mackie et al., 
1992; Gebremedhin et al., 1999). The CB1 receptor can also activate different members of 
mitogen-activated protein kinases including p44/42 MAP kinase, p38 kinase and JUN-terminal 
87	
	
kinase through G-protein mediated pathways or pathways independent of G-proteins via arrestins 
(Pacher et al., 2006; Turu et al., 2010). Due to its complex signaling network, CB1 has been 
implicated in the pathology of many disorders and thus is a promising therapeutic target for 
ameliorating diseases including nausea, obesity, neurodegenerative disorders, pain and substance 
abuse disorders (Pacher et al., 2006; Mackie et al., 2006). However, despite extensive efforts to 
generate cannabinoid-based therapeutics, only three medications from cannabinergic compounds 
(i.e. Cesamet, Marinol and Sativex) are commercially available due to the extensive side effects 
associated with CB1 orthosteric ligands. Another CB1 ligand, SR141716A (rimonabant), which 
was initially developed as an anti-obesity drug, was withdrawn from the market due to its 
psychiatric side effects (Cridge et al., 2013).   
To overcome challenges posed by orthosteric ligands (ligands which compete with the 
endogenous ligands for the same site), recent research in GPCRs including CB1 has shifted focus 
to allosteric modulators that bind to a topographically distinct site called the allosteric site. 
Allosteric modulators offer many therapeutic advantages over their orthosteric counterparts. 
First, due to less evolutionary pressure, allosteric binding pockets have amino-acid sequences 
which are not highly conserved like the orthosteric sites and thus are more specific for each 
receptor subtype. Second, the allosteric modulators have a ceiling effect due to their limited 
allosteric cooperativity and thus can be used to generate titrated pharmacological responses 
(Christopoulos et al., 2002; Bridges et al., 2008). Third, the allosteric modulators can be used to 
fine-tune endogenous signaling without affecting the spatial and temporal aspects of endogenous 
ligand-receptor signaling (Burford et al., 2013).              
Allosteric modulators, upon binding to a receptor, can induce an array of distinct 
conformations that can be very different from those stabilized by orthosteric ligands and thus 
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have expanded the spectrum of biological conformations between the inactive and active states. 
Several classes of allosteric modulators of CB1 have been identified (Figure 3.1), which include 
5-chloro-3-ethyl-N-(4-(piperidin-1-yl)phenethyl)-1H-indole-2-carboxamide (1, ORG27569) 
(Price et al., 2005), 1-(4-chlorophenyl)-3-(3-(6-(pyrrolidin-1-yl)pyridin-2-yl)phenyl)urea (2, 
PSNCBAM-1) (Horsewill et al., 2007), 3-(4-chlorophenyl)-5-(8-methyl-3-p-tolyl-8-
azabicyclo[3.2.1]octan-2-yl)isoxazole (3, RTI-371) (Navarro et al., 2009), the endogenous ligand 
(5S,6R,9E,11Z,13E,15S)-5,6,15-trihydroxyicosa-9,11,13-trienoic acid (4, lipoxin A4) (Pamplona 
et al., 2012) and 6-methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1H-indole (5, ZCZ011) 
(Ignatowska-Jankowska et al., 2015).  All of these ligands are positive allosteric modulators 
(PAMs) of the CB1 receptor in terms of enhancing orthosteric agonist binding. A family of 
peptide endocannabinoids (Pepcans) represented by pepcan-12 (6) has recently been reported to 
exhibit negative allosteric modulation (NAM) on the CB1 receptor at the levels of regulating the 
orthosteric agonist binding as well as on the signaling functions of CB1 receptor (Bauer et al., 
2012). Since allosteric modulators can induce distinct conformations than those induced by 
orthosteric ligands, they offer potential to generate pharmacological responses that may be 
difficult to achieve with orthosteric ligands alone. The different receptor states induced by 
allosteric modulators can be biased for a certain intracellular signaling pathways as is seen with 
many allosteric modulators including ORG27569 for the CB1 receptor and thus, they offer 
promising avenues to develop subtype-specific and pathway-specific therapeutics (Kenakin et 
al., 2012; Kenakin et al., 2010).  
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Figure 3.1. Structures of representative allosteric modulators of the CB1 receptor. 
 
Some in vivo pharmacological assessment indicated that these allosteric modulators can 
generate therapeutic effects relevant to various clinical therapies. For instance: 1 was 
demonstrated effective to inhibit reinstatement of drug-seeking behavior (Jing et al., 2014); 4 
was found to reduce β-amyloid-provoked neurotoxicity (Pamplona et al., 2012). The positive 
CB1 allosteric modulator 5 was shown to generate antinociceptive effects without psychoactive 
effects typically found in orthosteric ligands of CB1 receptor (Ignatowska-Jankowska et al., 
2015). Interestingly, 2 was found capable of reducing food intake and body weight in an acute 
feeding study (Horsewill et al., 2007). Thus, this scaffold holds promise for the development of 
anti-obesity drugs by targeting the allosteric sites. A recent SAR study of 2 has revealed that two 
structural variations can preserve the activity of 2. These include the replacement of the chloro 
group with either a fluoro (F) or a cyano (CN) group and the replacement of pyrrolidine ring 
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with N,N-dimethyl amino group. Using a calcium mobilization assay, these analogs exhibited a 
dose-dependent reduction of Emax values with the CB1 agonist CP55940, as expected for CB1 G-
protein NAMs (German et al., 2014). In order to increase the structural diversity from this 
scaffold, we designed novel analogs with the hypothesis that a pyrimidinyl ring can be employed 
to replace the pyridinyl ring of 2. This effort led to our syntheses and assessment of novel 
analogs 7a-7h and 8a-8u whose structures are shown in Figure 3.2.  
 
 
Figure 3.2. The designed and synthesized pyrimidinyl biphenyl ureas. (LDK numbers for the 
corresponding analogs are written in brackets. 
 
CHEMISTRY 
Dr. Dai Lu’s lab used the following procedures to synthesize the compounds 7a-h and 8a-u.  
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The syntheses of the target compounds 7 and 8 were achieved through the routes 
illustrated by Figure 3.3 and Figure 3.4 respectively. To obtain compounds 7a-7h, the synthesis 
of intermediate 3-(2-chloropyrimidin-4-yl)aniline (12) is critical. Coupling of the commercially 
available 2,4-dichloropyrimidine 9 with (3-nitrophenyl)boronic acid 10 under typical Suzuki 
reaction condition gave exclusively the 2-chloro-4-(3-nitrophenyl)pyrimidine 11. We found that 
this Suzuki coupling reaction only took place at the 4-chloro position of starting material 9, 
whilst its 2-chloro group was spared. The structure of the Suzuki coupling product 11 was 
confirmed by NOESY signals between the protons H-8 and H-12 with proton H-5 of 9 (see 
supporting information for 2D 1H NMR of 9). Upon reduction of 9 catalyzed with tin chloride 
dihydrate, the desired intermediate 3-(2-chloropyrimidin-4-yl)aniline (12) was obtained in an 
acceptable yield (45%). Reaction of the pyrimidinyl aniline 12 respectively with properly 
substituted isocyanate (13a-13f) yielded the key intermediates 14a-14f. Thereafter, amination of 
the pyrimidinyl ring of individual 14 with either pyrrolidine or N,N-dimethyl amine in THF 
generated the final compounds 7a-7h. 
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Figure 3.3 Synthesis of compounds 7a-7h.  Reagents and conditions: (i) Na2CO3, Pd(PPh3)4, 
DME, H2O; 90 oC, 7 h, 60%; (ii) SnCl2.2H2O, DCM/MeOH (1:1), 0 oC then reflux at 60 oC, 4 h,  
45%; (iii) DCM, 0 oC to rt, 2 h,  60-80%; (iv) pyrrolidine (for 7a-7d) or N,N-dimethyl amine (for 
7e-7h), THF, reflux, 100 oC, 2-4 h, 60-80%. LDK numbers for the corresponding analogs is 
written in brackets. 
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Figure 3.4 Synthesis of Compounds 8a-8t.  Reagents and conditions: (i) amine 15 (15a: 
pyrolidine; 15b: NH(CH3)2; 15c: MeNHEt; 15d: NH(Et)2; 15e: piperidine; 15f: 
cyclopropylamine; 15g: azitidine), THF, rt, 2 h,  77.3%-80%; c) ; (ii) Na2CO3, Pd(PPh3)4, 1,4-
dioxane, H2O (4:1), 110 oC, 10 h, 60-65%; (iii) 10% Pd/C, H2, EtOAc or ethanol, rt, 4 h, 90-
95%; (iv) corresponding phenyl isocyanate 13, DCM, 0 oC-rt, 2 h, 65-85%; (v) LiOH, THF/H2O, 
rt; (vi) BBr3, DCM, 0 oC-rt. LDK numbers for the corresponding residues is written in brackets. 
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To synthesize the compounds of series 8, we first tried to obtain compound 18 bearing a 
chloro functionality (R=Cl) so that the further variation at this position with different amino 
substitutions could be facilitated.   However, the Suzuki coupling reaction between 9 and 10 only 
produced compound 11, and no structure 18 (R= Cl) was formed. Therefore, we took the route 
illustrated in Figure 3.4 and aminated the 2,4-dichloropyrimidine 9 first. This yielded two 
regioisomers 16 and 17. The 4-amino pyrimidine 16 was obtained as the major product while the 
2-amino pyrimidine 17 is the minor product. The structures of individual compounds 16 and 17 
were determined by proton NMR, mass and compared to data reported in the literature. Coupling 
the 4-amino pyrimidine 16a-16g, respectively with (3-nitrophenyl)boronic acid 10 under Suzuki 
reaction conditions yielded the desired 2-(3-nitrophenyl)pyrimidin-4-amines 18a-18h in 
acceptable yields (46%-75%).  Hydrogenation of 18 produced the desired 2-(3-aminophenyl)-
pyrimidin-4-amines 19 in good yield (87-97%). Coupling the selected isocyanate 13 with amines 
19 yielded the final compounds 8a-8j, 8m and 8o-8t. The compound 8l (LDK1310) was further 
derived from 8k (LDK1302) through hydrolysis, and 8n (LDK1311) was further derived from 
8m (LDK1301) through removal of the methyl group by boron tribromide. 
3.3 Materials and Methods 
 
 
Cell line and culture conditions. Human embryonic kidney cells (HEK293T) was a kind gift 
from Dr. Randall Walikonis (Department of Physiology and Neurobiology, University of 
Connecticut). The cell line was cultured in DMEM medium with 10% FBS (v/v) and glucose 
(3.5 mg/ml). Cultures were maintained at 37 °C in humidified incubators with 5% CO2/ 95% air. 
CB1 expression and membrane preparation. HEK293 cells were seeded at approximately 
800,000 cells/100 mm dishes and transiently transfected using the calcium-phosphate 
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precipitation method. Membrane preparation was made as described previously (Chen et al., 
1987). Briefly, 24 hours post-transfection, the cells were harvested and washed with phosphate 
buffered saline (PBS). The cells were resuspended in PBS solution containing mammalian 
protease inhibitor cocktail ((4-2-aminoethyl) benzene-sulfonyl fluoride, pepstatin A, E-64, 
bestatin, leupeptin, and aprotinin) (Sigma-Aldrich, St. Louis, MO) followed by lysis by nitrogen 
cavitation at 750 psi for 5 min using a Parr cell disruption bomb. The cell lysate was spun at 500 
g for 10 min at 4ºC to remove nuclei, cell debris and intact cells. The supernatant was collected 
and spun at 100,000g for 45 min at 4ºC. The membrane containing pellet was resuspended in 
TME buffer (25 mM Tris-HCl, 5 mM MgCl2, and 1 mM EDTA, pH 7.4) containing 7% w/v 
sucrose. The protein concentration was determined using Bradford assay (Bradford, M.M., 
1976). The membrane preparation was then stored at -70ºC. 
Radioligand binding assay. To determine the allosteric parameters KB and α, ligand binding 
assays were performed as previously described (Ahn et al., 2012). Membrane preparation 
expressing the CB1 receptor was incubated with at least nine different concentrations (ranging 
between 100 pM and 100 µM) of unlabeled allosteric compound, in the presence of 0.5 nM 
[3H]CP55,940 (141.2 Ci/mmol, PerkinElmer Life Sciences (Boston, MA)) which is an 
orthosteric ligand of CB1 and was used as a tracer. TME  containing 0.2% fatty acid-free BSA 
was used as a buffer to make a final volume of 200 µl. Nonspecific binding was determined by 
incubating the membranes with a high concentration of unlabeled CP55,940 (1 µM). The 
reaction was terminated by adding 300 µl TME buffer containing 5% BSA and subsequent 
filtration through Whatman GF/C filter paper with a Brandel cell harvester. This was followed 
by washing with ice cold TME buffer and collecting the filter paper sections corresponding to 
each sample. Radioactivity was measured using liquid scintillation counting.  
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[35S]GTPγS evaluation. To evaluate the impact of the test compounds on the G-protein coupling 
efficiency of the CB1 receptor, GTPγS assays were performed as described previously (Ahn et 
al., 2012). Briefly, 7.5 µg membrane preparation expressing the CB1 receptor was incubated with 
a saturating concentration of CP55,940 (1 µM), 0.1 nM [35S]GTPγS (1250 Ci/mmol; 
PerkinElmer Life Sciences, Boston, MA), 5 µM GDP (Sigma, St. Louis, MO) and 0.1% (w/v) 
BSA in the absence and presence of varying concentrations of the test allosteric modulators. 
GTPγS binding assay buffer (50 mM Tris-HCl, pH 7.4, 3 mM MgCl2, 0.2 mM EGTA, and 100 
mM NaCl) was used to make a total volume of 200 µL and the membranes were incubated at 
30°C for an hour. Nonspecific binding was determined with 10 µM unlabeled GTPγS (Sigma, St. 
Louis, MO). For the controls, membrane preparations expressing CB1 receptor were treated with 
DMSO or a high concentration of the inverse agonist SR141716A (1 µM). Membrane 
preparations from the same cells not transfected with CB were also evaluated for the G-protein 
coupling levels to determine non-CB1 mediated GTPγS binding. The reaction was terminated by 
filtration through Whatman GF/C filter papers followed by washing with cold TME buffer. The 
filter paper sections were collected and radioactivity was measured by liquid scintillation 
counting. 
Data Analysis. All ligand binding and GTPγS assays were carried out in duplicate and at least 
three independent experiments were performed for each curve. For the ligand binding assays, 
data are presented as a mean with the corresponding 95% confidence limits. Data were analyzed 
by nonlinear regression using Prism 6.0 (Graphpad Software Inc., San Diego, CA) as previously 
described (Ahn et al., 2012). 
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3.4 RESULTS AND DISCUSSION  
The synthesized analogs were firstly evaluated for allostery, using the orthosteric agonist, 
CP55,940 and two key parameters: KB, the equilibrium dissociation constant of the allosteric 
modulator which reflects the affinity of the allosteric modulator for the receptor and α, the 
binding cooperativity factor which defines the magnitude and direction of the allosteric effect on 
the binding of the orthosteric ligand, when both occupy the receptor. Modulators with an α>1 
promote orthosteric ligand binding and are classified as positive allosteric modulators (PAMs) 
whereas modulators with α<1 inhibit orthosteric ligand binding and are classified as negative 
allosteric modulators (NAMs). Compounds with no allosteric activity on orthosteric ligand 
binding have an α equaling to 1 and are classified as silent allosteric modulators.  
 To evaluate the scaffold 7 and 8, we first compared 7a (LDK1283) and 8a (LDK1286) 
with the lead compound 2. The results shown in Table 3.1 and 3.2 (entry 2 and 10) suggested 
that replacing the pyridine ring of 2 with a pyrimidine ring reduced the binding affinity while the 
modulation on orthosteric ligand binding were enhanced (i.e. the α values are increased). This 
promoted our further investigation of the two new scaffolds by optimizing the substituents. We 
synthesized and assessed compounds 7b-7h and their counterpart compounds 8b-8h. The results 
shown in Table 3.1 (entry 3-9) and Table 3.2 (entry 11-17) revealed that the scaffold 7 and 8 do 
not show significant difference in binding affinity (KB) and binding cooperativity factor (α) 
except when the A ring was substituted with a para-cyano group and the pyrimidine ring was 
substituted with a pyrrolidinyl group (8d (LDK1288)). It also appears that a N,N-dimethyl amino 
substituent on the pyrimidinyl ring is suboptimal than a pyrrolidinyl group within each series of 
compound from scaffold 7 and 8. By far, only compound 8d (LDK1288) showed activity 
comparable to the lead compound 2.  
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A cyano group is a strong electron-withdrawing group (EWG). To investigate if other 
substituent on the phenyl ring A can increase the binding affinity and allosteric effects, we 
synthesized and assessed the compounds 8i-8n (Table 3.2), which bear either various EWG 
including CF3 (8i (LDK1304)), acetyl (8j (LDK1303)), ethoxyacyl (8k (LDK1302)) and COOH 
(8l (LDK1310)) or an electron-donating group (EDG) such as OMe (8m (LDK1301)) and OH 
(8n (LDK1311)). However, none of them surpassed the cyano-substituted compound 8d 
(LDK1288). Introducing EDGs on the phenyl ring A (i.e. compound 8m (LDK1301) and 8n 
(LDK1311)) significantly reduced the binding affinity to the allosteric site. Some of the EWGs 
are able to retain some binding affinity to the allosteric site (i.e. 8i (LDK1304) and 8k 
(LDK1302)). These suggested that variation of the electron density of the phenyl ring A alone is 
unable to enhance the binding affinity. It seems that the cyano group is not only to polarize the 
adjacent electron density on the A ring but also is likely involved in the molecular recognition 
process. The multiple biological functions of a cyano group have been well recognized (Fleming 
et al., 2010). Its functions include serving as carbonyl and halogen bioisosteres, a hydroxyl and 
carboxyl surrogate, an inducer of non-specific dipole interactions with amino acids and metal 
ions, and functionality able to replace a conserved water molecule from the binding domain 
(Fleming et al., 2010). Expulsion of a conserved water molecule from the binding domain by a 
cyano group may provide additional entropic improvement of binding affinity (Comer et al., 
2001; Levinson et al., 2014). 
 
 
 
 
 
 
 
 
99	
	
Table 3.1. Allosteric parameters of analogs derived from scaffold 7 (7a-7h). 
 
 
 
 
aKB : equilibrium dissociation constant of a potential allosteric ligand. bα: binding cooperativity 
factor for the tested allosteric modulator. The two allosteric parameters were tested using 
[3H]CP55,940 as the orthosteric ligand.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Entry Compd R1 R2 KB (nM)a αb 
1 2 p-Cl N-Pyrrolidinyl 54.3 (21.9-134.6) 7.3 
2 7a (LDK 1283) p-Cl N-Pyrrolidinyl 
226.9 
(61.8-832.2) 11.6 
3 7b (LDK1284) p-Br N-Pyrrolidinyl 
394.9  
(79.3-1964) 16.8 
4 7c (LDK 1297) p-F N-Pyrolidinyl 
195.6  
(113.8-336.1) 3.5 
5 7d (LDK1285) p-CN N-Pyrrolidinyl 
167.8  
(57.1-492.1) 10.5 
6 7e (LDK1293) p-F N(CH3)2 
1116  
(506.6-2459) 7.3 
7 7f (LDK1292) p-CN N(CH3)2 
416.6  
(308.1-563.2) 6.1 
8 7g (LDK1298) p-I N(CH3)2 
965.3  
(629.0-1481) 2.7 
9 7h (LDK1295) m-F N(CH3)2 
967.4  
(540.3-1722) 2.5 
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Table 3.2. Allosteric parameters of analogs derived from scaffold 8 (8a-8q). 
 
 
 
 
 
Entry Compd R1 R2 KB (nM)a αb 
1 2 p-Cl N-Pyrrolidinyl 54.3 (21.9-134.6) 7.3 
10 8a (LDK1286) p-Cl N-Pyrrolidinyl 
264.4  
(61.9-1129) 18.1 
11 8b (LDK1287) p-Br N-Pyrrolidinyl 
101.9  
(32.8-316.9) 6.1 
12 8c (LDK1294) p-F N-Pyrrolidinyl 
222.9  
(154.2-322.1) 4.9 
13 8d (LDK1288) p-CN N-Pyrrolidinyl 
49.1  
(27.9-86.3) 4.6 
14 8e (LDK1290) p-F N(CH3)2 
1221  
(849.6-1755) 5.2 
15 8f LDK1289) p-CN N(CH3)2 
313.3  
(216.2-454.2) 4.5 
16 8g LDK1296) p-I N(CH3)2 
997.1  
(480.7-2068) 2.5 
17 8h (LDK1291) m-F N(CH3)2 
669.8  
(173.6-2584) 2.0 
18 8i (LDK1304) p-CF3 N-Pyrrolidinyl 
144.2 
(85.8-242.4) 3.8 
19 8j (LDK1303) p-CH3C(O) N-Pyrrolidinyl 
2108 
(1299-3422) 2.5 
20 8k (LDK1302) p-EtOC(O) N-Pyrrolidinyl 
463.0  
(51.8-4132) 1.6 
21 8l (LDK1310) p-COOH N-Pyrrolidinyl NB
c NBd 
22 8m (LDK1301) p-OCH3 N-Pyrrolidinyl 
1826 
(991.7-3364) 3.8 
23 8n (LDK1311) p-OH N-Pyrrolidinyl NB
c NBd 
24 8o (LDK1300) m-CN N-Pyrrolidinyl 
1980  
(388.1-10100) 1.5 
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aKB : equilibrium dissociation constant of a potential allosteric ligand. bα: binding cooperativity 
factor for the tested allosteric modulator. The two allosteric parameters were tested using 
[3H]CP55,940 as the orthosteric ligand. cNB: no detectable binding to the receptor using up to 32 
µM of test compound. 
 
Table 3.3. Allosteric parameters of analogs derived from scaffold 8 (8p-8t). 
 
 
 
                                                             
entry Compd R KB (nM)
a αb 
13 8d (LDK1288)  
49.1  
(27.9-86.3) 4.6 
25 8p (LDK1312)  
211.0  
(100.7-442.0) 4.5 
26 8q (LDK1309)  
66.4  
(24.9-176.4) 3.2 
27 8r (LDK1307)  
69.6  
(20.1-240.3) 4.8 
28 8s (LDK1306)  
206.9 
 (110.3-388.1) 4.5 
29 8f (LDK1289)  
313.3  
(216.2-454.2) 4.4 
30 8t (LDK1308)  
97.7 
 (13.4-711.0) 1.7 
     
aKB : equilibrium dissociation constant of a potential allosteric ligand. bα: binding cooperativity 
factor for the tested allosteric modulator. The two allosteric parameters were tested using 
[3H]CP55,940 as the orthosteric ligand.  
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Following the identification of 8d (LDK1288), we investigated if other amino substituents on the 
pyrimidine ring can enhance activity (Table 3). We reduced the ring size to a 4-membered 
azetidinyl ring (8p(LDK1312)). This led to a decline of KB. When the ring size was increased to 
a 6-membered piperidinyl ring (8q (LDK1309)), it showed a KB comparable to 8d (LDK1288) 
with slightly reduced binding cooperativity factor (α).  This promoted our synthesis of analogs 
with acyclic amino substituents of the pyrimidinyl ring (i.e. 8r-8t). The results (entry 27-29, 
Table 3.3) indicated that only the N,N-diethyl amino group (8r (LDK1307)) preserve the activity 
of 8d (LDK1288). The results from 8r to 8t indicated that a dialkyl amino group is preferred as 
the substituent on the pyrimidinyl ring and each of the alkyl substitutions should be greater than 
methyl.  
 In summary, the efforts using pyrimidine in lieu of the pyridine ring led to two 
compounds (i.e. 8d (LDK1288) and 8r (LDK1307)) showing similar binding affinity (KB) to the 
allosteric site as the lead compound 2. Their allosteric effects on orthosteric agonist binding (i.e. 
the α values) are comparable to 2. The graphs for the analogs evaluated are shown in Figures 3.5-
3.10. 
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Figure 3.6 Binding curves for 2 (PSNCBAM-1) and analogs 7A-7D. The binding curves show 
the impact of varying concentrations of test compounds 2 (A), 7a (B), 7b (C), 7c (D) and 7d (E) 
on the binding of [3H]CP55,940. 
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Figure 3.6 Binding curves for analogs 7e-7h. The binding curves show the impact of varying 
concentrations of test compounds 7e (A), 7f (B), 7g (C) and 7h (D) on the binding of 
[3H]CP55,940. 
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Figure 3.7 Binding curves for analogs 8a-8f. The binding curves show the impact of varying 
concentrations of test compounds 8a (A), 8b (B), 8c (C), 8d (D), 8e (E) and 8f (F) on the binding 
of [3H]CP55,940. 
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Figure 3.8 Binding curves for analogs 8g-8l. The binding curves show the impact of varying 
concentrations of test compounds 8g (A), 8h (B), 8i (C), 8j (D), 8k (E) and 8l (F) on the binding 
of [3H]CP55,940 . 
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Figure 3.9 Binding curves for analogs 8m-8p. The binding curves show the impact of varying 
concentrations of test compounds 8m (A), 8n (B), 8o (C) and 8p (D) on the binding of 
[3H]CP55,940. 
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Figure 3.10 Binding curves for analogs 8q-8t. The binding curves show the impact of varying 
concentrations of test compounds 8q (A), 8r (B), 8s (C) and 8t (D) on the binding of 
[3H]CP55,940. 
 
 
To further confirm the value of the novel allosteric modulators, compounds 8d (LDK1288), 8r 
(LDK1307), 7a (LDK1283), 8a (LDK1286) and 7d (LDK1285) were selected to compare with 
2 in a [35S]GTPγS binding assay indicative of G protein coupling. The results were shown in 
Figure 3.11.  In the functional assay, compounds 7a (LDK1283) and 8a (LDK1286) are weaker 
antagonists than 2 in reducing the G-protein coupling to the CB1 receptor. In contrast, 
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compounds 7d (LDK1285) and 8d (LDK1288) showed potency comparable to 2 in reducing the 
G-protein coupling. Notably, although 7d (LDK1285) has a weaker binding affinity to the 
allosteric site than 8d (LDK1288) and 8r (LDK1307), it displayed potency similar to 8d 
(LDK1288) and 2 in the functional assay. This was indicated by their relative potency at the 0.3 
µM testing concentration in the [35S]GTPγS binding assay. In combination with the allosteric 
binding parameters, we conclude that compounds 7d (LDK1285) and 8d (LDK1288) are viable 
CB1 allosteric modulators showing a similar binding profile and functional activity to 2.  
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Figure 3.11 CP55,940-induced GTPγS levels in the presence and absence of varying 
concentrations of test allosteric modulators. HEK293 cell membranes expressing the CB1 
receptor was tested for GTPγS levels in the absence and presence of compounds (A) 
PSNCBAM-1 (2), (B) 7a (LDK1283), (C) 7d (LDK1285),  (D) 8a (LDK1286), (E) 8d 
(LDK1288)  (F) 8r (LDK1307) at the indicated concentrations in the presence of CP55,940 (1 
µM). The basal levels of [35S]GTPγS binding were also measured in the absence of any 
orthosteric and allosteric ligand (Basal CB1), and the inhibition of it was tested by treatment with 
SR141716A (1 µM). Data are presented as a percentage of the GTPγS levels in the presence of 
CP55,940 (1µM). Each data point represents the mean ± SE (error bars) of at least three 
independent experiments performed in duplicate. Non-CB1-mediated GTPγS levels were 
measured by obtaining [35S]GTPγS binding to membrane preparations transfected with empty 
vector PCDNA3.1 (PCDNA transfected). 
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3.5 Conclusion and Future Directions 
The recent identification of CB1 allosteric modulators indicated a new approach for 
developing safer therapeutics based on regulating the pharmacologically important CB1 receptor. 
Unlike CB1 orthosteric ligands, which typically present undesired psychotropic and psychiatric 
side effects, allosteric modulators have a better chance to avoid untoward side effects. This is 
because modulation of the receptor can be more finely regulated. Furthermore, if biased 
signaling pathways are utilized, signal transduction is more pathway-specific. In contrast to the 
vast structural diversity of CB1 orthosteric ligands, the structural diversity of CB1 allosteric 
modulators are fairly limited. This work identified novel lead compounds from the biphenyl 
ureas that possess a pyrimidine ring in their structures. The new compounds showed biological 
activities comparable to the well-established CB1 allosteric modulator PSNCBAM-1(2) that has 
a pyridine moiety. In comparison with pyridine, the pyrimidine structure offers more synthetic 
versatility. It has a π-electron density decreased to an even greater extent than pyridine (Brown et 
al., 2009). Therefore, nucleophilic aromatic substitution is facilitated. Synthetically, the electron-
deficient nature of pyrimidine accounts for better opportunities than pyridine when nucleophilic 
aromatic substitution chemistry is employed in functionalization of the electron-deficient 
heteroaromatic ring (Brown et al., 2009). Collectively, the newly identified pyrimidinyl biphenyl 
urea analogs provide new opportunities for the development of novel and potent CB1 allosteric 
modulators.  
Since these allosteric modulators demonstrate a paradoxical behavior of improving 
binding affinity of orthosteric ligands, yet decreasing G-protein coupling efficacy of orthosteric 
ligands which is similar to what is seen with indole-2-carboxamides, it will of interest to 
investigate whether these ligands also demonstrate a positive modulation of β-arrestin mediated 
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pathways such as ERK1/2, JNK1/2/3 etc. Further investigation of different kinases impacted by 
these analogs may help to better evaluate how these analogs manipulate different signaling 
pathways mediated by CB1. Also, investigation of these allosteric modulators in anti-obesity 
animal models will help translate the efficacy of these compounds from cellular models to 
animal models.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
114	
	
CHAPTER 4 
Identifying the Allosteric Binding Site on the CB1 Receptor 
 
4.1 Background 
Despite the advantages posed by allosteric modulation of CB1 for developing therapeutics, 
structure-based drug design is difficult for CB1 due to lack of information regarding the site(s) of 
binding of allosteric modulators. The difficulty in crystallizing these largely hydrophobic 
receptors further hinders the identification of key motifs that form the allosteric binding pocket 
on the CB1 receptor. Different modeling and experimental data generated by different 
researchers have identified three different allosteric sites (Fay et al., 2012; Shore et al., 2013; 
Stornaiuolo et al., 2015)). However, no consensus exists so far as to which of these models truly 
identifies the allosteric binding site. In our efforts to identify the allosteric binding site on the 
CB1 receptor, we chose a chimeric receptor construct approach to evaluate which regions of the 
receptor may be involved in the binding of allosteric modulators, ORG27569 and PSNCBAM-1. 
Chimeras of CB1 and CB2 were constructed where portions of low-affinity sequences of CB2 
replaced the corresponding pieces of high affinity sequences from the CB1 receptor. Since these 
allosteric modulators bind to CB1 and not CB2 (Ahn et al., 2012; Horsewill et al., 2010), the 
chimeric constructs were evaluated for loss of binding affinity to identify motifs that may 
involve residues important for binding of allosteric modulators. In this chapter, we piloted this 
approach to negate some of the possible hypothesis of allosteric binding site and identify a 
region that may play a key role in allosteric ligand binding. This data will lay the basis for 
further investigating the regions that may be involved in binding of these allosteric modulators. 
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4.2 Introduction 
Research in cannabinoid-based therapeutics has been severely impeded by the lack of subtype-
specific drugs for CB1 and CB2 which may cause side-effects. The two subtypes of the 
cannabinoid receptor family, i.e. CB1 and CB2, have a transmembrane sequence identity of 51% 
(Shire et al., 1996) making subtype specific ligands that target this region in CB1 difficult to 
generate. The discovery of ORG27569 as an allosteric modulator of the CB1 receptor has 
demonstrated that at least one allosteric site exists on the CB1 receptor. While most orthosteric 
ligands like CP55,940 bind non-selectively to both CB1 and CB2, ORG27569 doesn’t bind CB2 
up to 10 µM (Ahn et al., 2012). Identifying the amino acid residues that confer specificity of 
binding to ORG27569 can help in defining the allosteric binding site. Identification of the 
allosteric binding site will allow an understanding of the mechanisms by which ORG27569 
displays a contradictory profile i.e it increases CP55,940 binding while decreasing G-protein 
coupling associated with CP55,940 (Ahn et al., 2012). Identifying the allosteric binding pockets 
will also allow structure-based drug design for modulators with improved allostery at the CB1 
receptor. 
Three different research groups have utilized different techniques to identify the putative 
allosteric binding pockets at the CB1 receptor and investigate the mechanisms that could explain 
the contradictory profile of ORG27569 being a PAM for CP55,940 binding but an allosteric 
antagonist for G-protein coupling. However all three of the putative allosteric binding sites 
identified by these groups do not seem to overlap. Fay and colleagues (Fay et al., 2012) 
investigated how different conformations of the receptor are induced by ORG27569 which could 
explain the molecular pharmacology of ORG27569. Site-specific fluorescent labeling of the 
receptor was done to identify conformational changes in CB1 upon binding of ORG27569. A 
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mutant of CB1 lacking the cysteines was generated with only Cys-257 and Cys-264 not mutated 
as these two cysteines are involved in a disulfide bond formation and are necessary to retain a 
functional receptor. A cysteine was then introduced in the mutant at residue 342 which lies in the 
TM6 on the intracellular side. A bimane label was then used to label the cysteine at residue 342 
and changes in fluorescence were monitored with the label introduced. The mutation was 
introduced at residue 342 as changes in TM6 have been reported for GPCR activation. The 
authors demonstrated that changes in fluorescence intensity occurs upon interaction of the 
mutant with agonist CP55,940. However, incubation of the receptor preparations with 
ORG27569 blocked the change in fluorescence intensity. It was thus concluded that ORG27569 
arrests the receptor in an agonist-bound non-G-protein signaling state by blocking the 
movements in TM6 from the agonist). Further investigations by this group identified a disulfide 
bond in the N-terminus of the receptor to play an important role in the allosteric effects seen with 
ORG27569 and PSNCBAM-1. The disulfide bond was formed by Cys98 and Cys107. 
Interestingly, they found that reduction of this disulfide bond in the amino-terminus resulted in 
enhancement of the cooperativity effects seen with ORG27569 and PSNCBAM-1. The authors 
suggested that the allosteric modulators may bind to this region and alter the dissociation of the 
orthosteric ligand CP55,940, thus enhancing CP55,940 binding. However, the studies lacked a 
direct evidence to show the impact of the disulfide bridge on binding affinities of the allosteric 
ligands, thus suggesting that the disulfide bond may play an indirect effect of the allostery at CB1 
receptor but may not be be part of the allosteric binding pocket. 
Shore and colleagues utilized molecular modeling, mutagenesis and G-protein coupling assays to 
define the allosteric binding pocket for ORG27569 (Shore et al., 2013). The approach for the 
identification of the allosteric site was based on the observation that ORG27569, in ligand 
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displacement assays, decreases the equilibrium binding of SR141716A, an inverse agonist of 
CB1 receptor. Thus ORG27569 may have an overlapping binding site with SR141716A. 
Computational modeling of ORG27569 on the CB1 receptor was done with docking the ligand 
manually in the TMH3-6-7 region. Modeling data suggested that the binding site for ORG27569 
overlaps with the binding of SR141716A. Residues K1923.28, F2003.36, W2795.43 and W3566.48, 
which have previously been reported to be important for SR141716A binding were mutated to 
alanine and tested for their impact on G-protein coupling efficacy of CP55,940 with ORG27569. 
Incubation of CB1Wt membrane preparations with ORG27569 (1µM) showed a complete loss of 
CP55,940 induced G-protein coupling. Mutants that would cause a loss of ORG27569 binding 
would demonstrate decrease in the antagonism of G-protein coupling by ORG27569, which will 
be seen by higher G-protein coupling levels. Only K192A mutant showed an increase in G-
protein coupling in presence of ORG27569 compared to CB1WT, suggesting this amino acid 
plays an important role in the binding of ORG27569. The computational modeling suggested that 
the piperidine nitrogen of ORG27569 is involved in forming hydrogen bonding with K192. 
However, K192 has also been reported to directly impact the binding of CP55,940 (Song et al, 
1996, Shim et al., 2010). The authors showed that K192A mutant demonstrated a high EC50 (225 
nM) for CP55,940-induced G-protein coupling because of its role in CP55,940 binding. 
However, ORG27569 could only antagonize 41% of the levels exhibited by CP55,940. Also, 
since this residue is conserved between CB1 and CB2, this mutation does not describe why 
ORG27569 binds to CB1 and not CB2. The computational modeling also predicts F268 from the 
EC2 loop to form aromatic stacking interactions with the indole-ring of ORG27569. No 
mutagenesis studies were reported for this residue.  
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Stornaiuolo and colleagues identified an entirely different site of binding for ORG27569 
(Stornaiuolo et al., 2015). The group utilized computational modeling techniques using 
sphingosine 1-phosphate receptor to build a homology model of CB1 receptor, to identify five 
different possible allosteric binding sites. Out of all the sites, the few residues that were different 
in CB1 and CB2 were mutated in CB1 to the corresponding residues in CB2 receptor. 
Fluorescence binding assays were done using a fluorescent tetra-methyl-rhodamine (TAMRA) 
labeled form of the CB1 inverse agonist, AM251, namely T1117. The mutations were first 
evaluated for their impact on T1117 binding. The mutations that did not affect T1117 binding 
were then evaluated for change in T1117 binding in the presence of ORG27569. It has been 
previously demonstrated by the same group (Bruno et al., 2014) that binding of T1117 to 
CB1WT is negatively impacted by ORG27569. Loss of T1117 binding would suggest that the 
mutations are not important for ORG27569 binding. If however, no change in T1117 binding is 
seen in the presence of ORG27569, the mutation is considered important for ORG27569 binding. 
Photoactivatable analogs of ORG27569 were also utilized to cross-link with CB1 and residues 
important for binding were then evaluated from mass-spectrometry. The authors identified an 
intracellular binding site for ORG27569 (Stornaiuolo et al., 2015). This was in complete contrast 
to the site(s) identified by the other group of researchers which suggested more extracellular sites 
of binding. Mutational analysis identified three mutations C1.55Y, H2.41L and F4.46L (P2 in the 
intracellular regions of TM1,2 and 4), that demonstrated no loss of T1117 binding upon 
incubation with ORG27569, suggesting these residues to be important for binding of ORG27569. 
The mass-spectrometry data identified two serines, S2.45 and S3.42 to be important for the binding 
of ORG27569. The mass-spectrometry data did not report the residues found important from 
mutagenesis to be involved in cross-linking although the residues belong to the same region. The 
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authors negated two other extracellular pockets (P3 in the transmembrane regions of TM3 and 4; 
and P4 in the extracellular regions in TM3 , 6 and 7) identified from modeling based on one 
mutant tested from each region. Also, another pocket identified by computational analysis in the 
intracellular surface of TM 1, 7 and 8 was evaluated by two mutants, I7.51V and F8.54A. The I7.51V 
demonstrated no loss in T1117 binding in the presence of ORG27569, suggesting this residue to 
be important for ORG27569 binding.. However, this mutant was not pursued further because 
F8.54A of the same pocket in exhibited loss in T1117 binding in the presence of ORG27569. 
Thus, overall, different researchers have identified very different sites of binding of ORG27569 
and none agree with each other (Fay et al., 2012; Shore et al., 2013; Stornaiuolo et al., 2015). 
Also, no investigations into the binding site for PSNCBAM-1 have been reported.  
To identify the regions of the CB1 receptor important for ORG27569 and PSNCBAM-1 binding, 
we chose a chimera construction approach. CB1 and CB2 have a high degree of conservation in 
the transmembrane regions (Shire et al., 1996). As a result, most of the orthosteric ligands such 
as CP55,940, WIN55,212-2 are not subtype-specific and bind both CB1 and CB2. However, most 
of the allosteric modulators of the CB1 receptor known so far such as ORG27569, PSNCBAM-1 
show undetectable binding to the CB2 receptor (Ahn et al., 2012; Horsewill et al., 2010). We 
took advantage of this subtype selectivity and constructed chimeras of CB1 and CB2, where no -
binding sequences of CB2 replaced the corresponding pieces of high affinity sequence in CB1 to 
evaluate loss of binding affinity of allosteric modulators to identify the CB1 allosteric site(s). 
Two pharmacophorically different allosteric modulators, ORG27569 and PSNCBAM-1 (Figure 
4.1) were chosen to identify whether multiple binding sites or the sane site exists on CB1 
receptor for these allosteric modulators. 
120	
	
 
Figure 4.1 Structures of some allosteric modulators of the CB1 receptor. 
4.3 Materials and Methods 
Construction of chimeric receptors and site-directed mutagenesis. For the construction of 
chimeric receptors, sequences recognized by AgeI (ACCGGT) and NotI (GCGGCCGC) 
enzymes were introduced in CB1 and CB2 vectors at the beginning and end of the regions which 
were to be exchanged. The two vectors were digested and run on an agarose gel to separate the 
sliced regions. The regions of interest of CB1 and CB2 were cut out of the agarose gel and the 
DNA was extracted. The two regions were ligated by DNA ligase and the sequences for AgeI 
and NotI were deleted by site-directed mutagenesis to form the chimeric constructs. For some of 
the chimeras which had small inserts such as those of the EC3, EC2, IC1 and IC2 loops, 
sequential site-directed mutageneis was performed (QuikChange, Stratagene, La Jolla, CA) to 
construct the chimeras using the human CB1 cDNA cloned into pcDNA3.1 as a template, 
following the manufacturer’s protocol. Nomenclature used for chimeric receptors is: CB1/CB2 
(region replaced) as previously described (Shire et al., 1996). All the chimeric mutations were 
confirmed by DNA sequencing. 
Expression of constructs and membrane preparation. Wild type-CB1 or the CB1/CB2 
constructs were expressed in HEK293 cells and membrane prepared as described previously 
(Ahn et al., 2012). Briefly, HEK293 cells were seeded at 1,00,000 cells in 100 mm dishes. The 
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cDNA encoding CB1 or the newly generated constructs was transiently transfected using 
calcium-phosphate precipitation method. 24h post-transfection, the cells were harvested and 
washed with phosphate-buffered saline (PBS) and resuspended in PBS containing mammalian 
protease inhibitor cocktail ((4-2-aminoethyl) benzene-sulfonyl fluoride, pepstatin A, E-64, 
bestatin, leupeptin, and aprotinin) (Sigma-Aldrich, St. Louis, MO). The cells were lysed by 
nitrogen cavitation and the lysate collected. The lysate was spun at 500 g for 10 min to remove 
nuclei and cell debris, followed by centrifugation of the supernatant at 100,000 g for 45 min at 
4°C. The pelleted membrane is then resuspended in TME buffer (25 mM Tris-HCl, 5 mM 
MgCl2, and 1 mM EDTA, pH 7.4) containing 7% w/v sucrose. 
Radioligand binding assays. To assess proper folding and expression of the chimeric receptors 
and that the chimeras do not impact the orthosteric site, the chimeric receptors were evaluated for 
their CP55,940 binding. Membrane preparations of the chimeric constructs were incubated with 
at least nine different concentrations of CP55,940 (ranging from 100 pM to 1 µM) in the 
presence of a fixed concentration of [3H]CP55,940 (141.2 Ci/mmol, PerkinElmer Life Sciences 
(Boston, MA)), typically at its KD as previously described (Antona et al., 2006). 
For determining the allosteric parameters KB and α, the receptor preparations were incubated 
with nine different concentrations of ORG27569 or PSNCBAM-1 (ranging from 100 pM to 100 
µM) in the presence of a fixed concentration of [3H]CP55,940 as previously described (Ahn et 
al., 2012). 
For both the assays described above, TME containing 0.2% fatty acid-free BSA was used as a 
reaction buffer to make a final volume of 200 µL. Unlabeled CP55,940 (1 µM) was incubated 
with membrane preparations to determine the non-specific binding. The reaction was incubated 
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at 30°C for an hour and the reaction was adding 300 µL of TME containing 5% BSA followed 
by filtration through Whatman GF/C filter paper using a Brandel cell harvester. The filter paper 
was washed with ice-cold TME buffer to reduce non-specific binding and radioactivity of the 
collected samples was measured.  
Data analysis. Each data point in the radioligand binding assays was performed in duplicate and 
each curve is generated from at least three independent assays. Data are presented as a mean with 
the corresponding 95% confidence limits. Data was analysed using nonlinear regression using 
Prism 6.0 (Graph pad Software Inc., San Diego, CA) as described previously (Ahn et al., 2012). 
The KB values of wild-type CB1 were compared with the mutants using analysis of variance 
(ANOVA) followed by Dunnett’s test. P<0.05 was considered statistically significant. 
4.4 Results and discussion  
In our efforts to identify the allosteric binding site(s), chimeric constructs of CB1/CB2 were made 
(as shown in Figure 4.2) based on two hypotheses. CB1/CB2 chimeras previously published to be 
functional and properly folded will also be used to guide chimera construction (Shire et al., 
1996). Following were the two hypothesis: 
1. Most of the positive allosteric modulators of CB1 including ORG27569, PSNCBAM-1 
decrease G-protein coupling suggesting that this allosteric modulator binding site(s) may 
overlap with the G-protein coupling site and physically preclude G-protein coupling. 
Modeling and mutational analysis of the CB1 receptor have demonstrated that the 
intracellular loop especially IC3 and C-terminus tail are regions where the G-protein may 
couple to (Shim et al., 2016). Thus, chimeric constructs of IC loops and the C-terminal 
tail were constructed. 
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2. The allosteric modulators of CB1 are highly subtype specific and do not bind to CB2, 
suggesting that there is a high sequence divergence at the allosteric binding site(s). The 
transmembrane regions show a high sequence homology of 70% in the transmembrane 
regions. However, the EC and IC loops have high sequence divergence. An allosteric 
binding site in the EC loops has been reported for some GPCRs such as mAChRs where 
mutation of an acidic sequence called EDGE in the M2 subtype to the corresponding 
neutral sequence LAGQ of M1 subtype resulted in reduced affinity of the allosteric 
modulator, Gallamine for M2 receptor subtype (Gnagey et al., 1999). Thus, chimeric 
mutants of the EC loops were constructed.  
To evaluate proper folding and expression of the receptor and to ensure that these mutations 
do not impact the orthosteric binding site, competition assays with [3H]CP55,940 were 
performed for the chimeric receptors. As seen in Table 1, none of the chimeric mutants 
except IC2 showed alterations in Ki values for CP55,940 compared to wild type CB1, 
suggesting that these mutations do not impact the orthosteric ligand binding site. This was 
not surprising since CP55,940 binds to both CB1 and CB2 with similar affinities and no TM 
regions were mutated. The chimeric mutants were further evaluated for their impact on the 
allosteric binding parameters, KB and α. Two pharmacophorically different allosteric 
modulators, ORG27569 and PSNCBAM-1 (Figure 4.1) were used and their allosteric 
parameters were evaluated. Statistical analysis of the allosteric parameters was performed 
versus wild type CB1 bound to the allosteric ligand under the same conditions. 
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Figure 4.2 Schematic representations of the amino acid sequences of CB1, CB2 and the 
CB1/CB2 chimeras. Amino acid sequences of the regions of CB1 that was replaced are shown 
in red and the regions of CB2 that were inserted are shown in green for the different chimeric 
mutants. The residues of the putative transmembrane regions which flank the points of 
digestion are shown in grey.   
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As shown in the Table 4.1, none of the chimeric mutants demonstrated any change in the 
allosteric parameters for PSNCBAM-1, suggesting that these regions do not play a key role in 
the binding of PSNCBAM-1. 
Interestingly, for ORG27569, some of the chimeric mutants showed a decrease in the binding 
affinity as reflected by high KB values as shown in Figure 4.3 and Table 1. In particular, the 
CB1/CB2 (EC2) chimera showed a statistically significant decrease in the binding affinity of 
ORG2756, thus suggesting the importance of this loop in the binding affinity of ORG27569. The 
difference in the impact of these mutants on ORG27569 versus PSNCBAM-1 suggests that these 
allosteric modulators may bind different sites on the CB1 receptor. Further investigations of these 
motifs may help identify the key amino acids that cause the preferential binding of ORG27569 to 
CB1 as compared to CB2. 
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Receptor 
CP55,940 
Binding ORG27569 Binding
a PSNCBAM-1 Bindinga 
Ki (nM) KB (nM) α KB (nM) α 
Wild Type 1.7 (1.2-2.6)  380 (271.6-531.5) 
 
5.2 54.3 (21.9-134.6) 7.3 
CB1/CB2 (C-tail) 2.9 (1.2-7.6) 296.8 (115-766) 14 62.9 (17.9-221) 9.6 
CB1/CB2 (IC1) 3.6 (1.7-5.5)b 1057 (738-1514) 6.7 138.3 (75.7-252) 4.5 
CB1/CB2 (IC2) NB ND ND ND ND 
CB1/CB2 (IC3) 1.2 (0.7-2.0) 502.3 (277.3-909.9) 3.8 78.5 (44.8-138) 4.0 
CB1/CB2 (EC2) 0.5 (0.1-1.9) 2265 (1486-3453)* 4.3 116.6 (36.5-373) 2.9 
CB1/CB2 (EC3) 2.8 (0.7-12.1) 881.2 (566-1372) 4.9 109.9 (39.4- 306) 3.0 
 
Table 4.1. Binding parameters for the different CB1/CB2 chimera mutants. The Ki values for 
[3H]CP55,940 binding to the wild-type and the CB1/CB2 chimera mutants is shown. For the 
allosteric modulators, ORG27569 and PSNCBAM-1, the parameters, KB and α are shown in the 
table. Data are presented as a median and the corresponding 95% confidence limits, from atleast 
three independent assays that were performed in duplicate. Asterisks depict the statistically 
significant differences between the parameters of chimeric mutants compared with the wild-type 
receptor using analysis of variance followed by Dunnett’s test. *, P < 0.05, **, P < 0.01, 
***, P < 0.001. NB: no detectable binding for [3H]CP55,940 was seen upto 32 µM. ND: not 
determined for ORG27569 and PSNCBAM-1 binding due to loss of [3H]CP55,940 binding. a: 
using [3H]CP55,940 as the orthosteric ligand. b data represents KD values for the chimera. 
 
127	
	
 
Figure 4.3 Binding curves of ORG27569 binding to CB1 wild-type and the different CB1/CB2 
chimeric mutants. The curves show comparison of modulation of [3H]CP55,940 binding by 
different concentrations of ORG27569 to the wild-type CB1 receptor and (A) CB1/CB2 (EC2) 
chimera, (B) CB1/CB2 (EC3) chimera, (C) CB1/CB2 (IC1) chimera, (D) CB1/CB2 (IC3) chimera 
and (E) CB1/CB2 (C-tail) chimera. *the CB1WT curve is not shown because different 
concentration of [3H]CP55,940 was used for determining the KB values.  
128	
	
4.5 Conclusions and Future Directions 
This project helps to identify the key motifs that are involved in the identification of the 
allosteric site on the CB1 receptor. Interestingly, we found that the extracellular loop EC2 
significantly altered the affinity parameter, KB for ORG27569. However, none of the tested 
mutants impacted the binding of PSNCBAM-1. This suggests that multiple allosteric sites may 
exist on the CB1 receptor. A reasonable argument for the extracellular loops to be involved in the 
allosteric binding site may be that it is because the allosteric site is extracellular in nature that 
CP55,940, which binds in the transmembrane region, is blocked from dissociating from the 
receptor due to an allosteric ligand residing above it, which increases the binding of CP55,490. 
Interestingly, the two extracellular loops show a high sequence divergence as shown in Figure 
4.2. Further investigations of the amino acid residues can help identify the individual amino 
acids that may be responsible for the binding of ORG27569. Many charged amino acids in the 
CB1 receptor in the EC2 loop are replaced by uncharged residues in the CB2 receptor and vice-
versa, which could explain the loss of charged interactions of ORG27569 upon binding to the 
CB2 receptor. Some of these residues include: 
1. Positively charged E258, which is replaced by an uncharged cysteine in the CB2 receptor. 
2. Positively charged K259, which is replaced by an uncharged proline in the CB2 receptor. 
3. Uncharged L260, which is replaced by a positively charged arginine in the CB2 receptor. 
4. Positively charged H270, which is replaced by an uncharged leucine in the CB2 receptor. 
Binding assays using point mutations replacing the CB1 residue for the corresponding CB2 
residues will help to identify key interactions which stabilize ORG27569 binding to the CB1 
receptor. 
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Once the amino acids that play a key role in the binding of these allosteric modulators are 
identified, further evaluation on how these residues affect G-protein coupling would help 
identify the mechanisms which cause a decrease in G-protein coupling efficacy with these 
modulators. Evaluation of these motifs for their impact on β-arrestin coupling efficacy is another 
area of interest that can be investigated.  
Identification of the allosteric binding sites at the CB1 receptor will provide a better 
understanding of the molecular mechanisms that govern allostery at the CB1 receptor. It will also 
aid in screening of additional compounds using virtual libraries that may provide improved 
properties like higher affinity and improved cooperativity with the receptors.	These studies will 
pave the way for a structure-based drug design for allosteric modulators of CB1 where the key 
amino acids in the allosteric pocket can be targeted to improve allostery at the CB1 receptor. 
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Chapter 5 
Conclusions and Future Directions 
 
In this thesis project, we aimed to improve our understanding of allosteric modulation of the CB1 
receptor by focusing on two important scaffolds that demonstrate allosterism. First, the indole-2-
carboxamide, which is the scaffold of ORG27569, was evaluated to identify the key chemical 
functionalities that are important for exhibiting allostery at the CB1 receptor. We identified that a 
critical length of the alkyl group on the indole ring is important for maintaining the allosteric 
parameters, KB and α. While a n-propyl chain improves the α value for orthosteric ligand 
binding, a n-hexyl chain improves the binding affinity (KB) of the allosteric modulator. We also 
identified that a dimethylamino substitution at the piperidinyl ring improves both the KB and α 
values. We also demonstrated that the linker length between the indole ring and the piperidinyl 
moiety, when shortened or extended resulted in loss of allostery. The importance of a EWG at 
the C5 position of the indole-ring was also demonstrated and that change in position of 
substituent results in a loss of binding affinity of the allosteric modulators. A SAR study was 
also done with a pyrimidinyl biphenylurea scaffold, which was a modified scaffold of the 
compound PSNCBAM-1. The SAR study identified that a cyanide moiety at the para position of 
the aromatic ring A demonstrated an improved KB value for both the regioisomers of this 
scaffold. We also identified that a diethylamino group substitution on the pyrimidine ring 
showed allosteric parameters similar to PSNCBAM-1. 
For both the scaffolds, it was further demonstrated that these positive allosteric modulators of the 
CB1 receptor were pathway-biased. They decreased G-protein coupling pathways of the CB1 
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receptor. Interestingly, they function via β-arrestin 1 mediated pathways as was demonstrated by 
ERK1/2 phosphorylation by these allosteric modulators. 
This project helps to demonstrate and appreciate that signaling via GPCRs is not linear. It has a 
pluridimensional nature and different conformations generated by different ligands cause 
manipulation of different signaling pathways. Thus, the same GPCR can exhibit signaling via 
different G-proteins or other signaling proteins such as β-arrestins.  Taking advantage of this, a 
GPCR can be directed to trigger different translational responses depending upon the ligand 
bound to the GPCR. Future work on this project may include using the best allosteric modulators 
identified here for translational evaluation in mice models. Since the ORG27569 has shown 
promise for the treatment of addiction (Jie et al., 2014), evaluation of the robust allosteric 
modulators identified in this project may be done to evaluate the efficacy of these compounds for 
the treatment of addiction. Also, evaluation of pyrimidinyl biphenylurea derivatives in mice 
models for the treatment of obesity may be pursued as PSNCBAM-1 has shown promise as an 
anti-obesity drug previously (Horsewill et al., 2010). 
Another goal of this thesis was the identification of allosteric site(s) on the CB1 receptor. We 
identified the EC2 loop as likely to play a critical role in the binding of the allosteric modulator, 
ORG27569 but not PSNCBAM-1. This suggests that the motifs that were evaluated for 
ORG27569 are not part of the binding site of PSNCBAM-1. This opens up the possibilities that 
more than one allosteric site may exist on the CB1 receptor. Moreover, the conformations 
induced by ORG27569 and its derivatives versus that induced by PSNCBAM-1 and its 
derivatives are likely different. Further, identifying which of the residues impact G-protein 
coupling inhibition by these allosteric modulators may be evaluated to understand the 
132	
	
mechanisms governing the contradictory impact of these allosteric modulators on orthosteric 
ligand binding and G-protein coupling. 
Further evaluation of the EC2 loop by single-site mutations will allow identification of the key 
amino acid residues that are important for binding of ORG27569. This project will add to the 
computational modeling of the allosteric site(s) on the CB1 receptor. This will further help in the 
strategic design of small molecules for lead identification and optimization, which is currently 
hindered by the paucity of reliable models of the CB1 receptor. 
Future directions of this project may include identifying differences in conformations of the CB1 
receptor upon binding to differentially biased ligands. For the CB1 receptor, three ligands with 
different functional selectivity may be utilized: 
1. Unbiased ligands such as 2-AG, which have been demonstrated to exhibit both G-protein 
dependent and β-arrestin dependent signaling (albeit with different kinetics). 
2. G-protein biased ligands such as CP55,940 which is a Gi- biased ligand. 
3. β-arrestin biased ligands such as the allosteric modulators ORG27569 and PSNCBAM-1 
identified in this project. 
Many FRET techniques such as FlAsh-based FRET are available that can be utilized to examine 
conformations (Hoffmann et al., 2005). For FlAsh-based FRET, specific tetracysteine sequence 
can be inserted in the intracellular loops of the CB1 receptor that are identified by small, 
membrane-permeant derivative of fluorescein, FlAsh (fluorescent arsenical hairpin binder). By 
transiently transfecting CFP-tagged Gi-fusion protein or β-arrestin protein, and treating the CB1 
receptor with the different ligands mentioned above, changes in conformations of the receptor 
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upon binding to the different ligands may be identified. This will add to the wealth of 
information available for the dynamic changes in GPCRs with differently signaling ligands. 
The current project identified modulation of one of the key kinases of the MAPK family, the 
ERK1/2. However, many other important downstream kinases other than ERK1/2 such as c-Jun, 
FAK, beta-catenin, CREB are present in cells, which may be differently impacted by treatment 
with the differentially-biased ligands. Future work on this project may include identifying how 
the biased ligands impact these downstream kinases. These future studies will help us to better 
understand the complex signaling pathways generated by different conformations of a receptor 
and their outcome. Finally, we need to learn how these impact animal models of diseases that can 
be treated via targeting CB1. Moreover, new biomarkers that are modified by these compounds 
can be identified by examining the RNA expression.  
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